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1. INTRODUCTION 
The pharmaceutical analysis is a branch of chemistry, which involves the series of 
process for the identification, determination, quantization, and purification. This is 
mainly used for the separation of the components from the mixture and for the 
determination of the structure of the compounds. The different pharmaceutical agents 
are as follows: 
1. Plants 
2. Microorganisms 
3. Minerals 
4. Synthetic compounds 
Based upon the determination type, there are mainly two types of analytical methods. 
They are as follows: 
1. Qualitative analysis: This method is used for the identification of the 
chemical compounds. 
2. Quantitative analysis: This method is used for the determination of the 
amount of the sample. 
Types of Analytical Methods 
Analytical methods are mainly of the following two types: 
1. Classical methods:  
1. Gravimetry: The weight of the sample is determined after the 
precipitation. 
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2. Titrimetry: The volume of the solution is determined after the reaction 
such as neutralization, complex formation, precipitate formation, and 
oxidation and reduction. 
3. Volumetry: The volume of the gas evolved by the reaction is 
determined. 
2. Instrumental methods:  
1. Electrochemical methods: Used for the measurement of the current, 
voltage, or resistance.  
  Examples: Conductometry: Measurement of the conductance. 
 Potentiometry: Measurement of the potential. 
 Coulometry: Measurement of the current. 
 Voltametry: Measurement of the current at specified 
voltage. 
2. Optical methods: Based upon the measurement of radiation absorbed 
or emitted  
Absorption methods : Visible, Ultraviolet (UV), Infrared (IR), Atomic 
Absorption Spectroscopy (AAS) 
Emission methods:  Plasma emission spectroscopy, flame 
spectroscopy, and fluorimetry. 
3. Chromatography: paper, High Pressure Liquid Chromatography 
(HPLC), Gas Chromatography (GC), ion exchange, Thin Layer 
Chromatography (TLC), and column chromatography. 
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4. Thermal methods: Differential Thermal Analysis (DTA), 
Thermogravimetric (TG), and Differential Scanning Calorimetry 
(DSC). 
5. Other methods: X-ray diffractometry, radioactive methods, mass 
spectrometry, refractometry and polarimetry. 
Pharmaceutical analysis deals not only with medicaments (drugs and 
formulations), but also with their precursors i.e. with the raw material whose degree 
of purity, which in turn decides the quality of medicaments. The quality of a drug is 
determined, after establishing its authenticity, which is carried by testing its purity and 
the quality of the pure substance in the drug and its formulations. 
HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC):           
 High-performance liquid chromatography is a chromatographic technique 
used to separate the components in a mixture, to identify each component, and to 
quantify each component .The method involves a liquid sample being passed over a 
solid adsorbent material packed into a column using a flow of liquid solvent. Each 
analyte in the sample interacts slightly differently with the adsorbent material, thus 
retarding the flow of the analytes. If the interaction is weak and the analytes flow off 
the column in a short amount of time, and if the interaction is strong, then the elution 
time is long. 
           Chromatography may be defined as a method of separating a mixture of 
components into individual components through equilibrium distribution between two 
phases. (Sharma B.K) 1 
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The schematic representation of an HPLC instrument typically includes a 
sampler, pumps, and a detector. The sampler brings the sample mixture into the 
mobile phase stream which carries it into the column. The pumps deliver the desired 
flow and composition of the mobile phase through the column. The detector generates 
a signal proportional to the amount of sample component emerging from the column, 
hence allowing for quantitative analysis of the sample components.  A digital 
microprocessor and user software control the HPLC instrument and provide data 
analysis. Some models of mechanical pumps in a HPLC instrument can mix multiple 
solvents together in ratios changing in time, generating a composition gradient in the 
mobile phase. Various detectors are in common use, such as UV/V is, photodiode 
array (PDA) or Refractive index (RI). 
CHROMATOGRAPHY AND ITS TYPES 
HPLC techniques are classified on the following types: 
• Based on the modes of chromatography (based on the polarity of stationary 
and mobile phase):  
Normal phase mode: Stationary phase is polar e.g., silica gel and mobile phase is 
non-polar. 
Reverse phase mode: Stationary phase is non-polar and mobile phase is polar. 
 In normal phase mode, non-polar compounds travel faster and are eluted first. 
This is because of less affinity between solute and stationary phase. Polar 
compounds are retained longer time in the column because of more affinity 
towards stationary phase and take more time to elute. 
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 In reverse phase mode, polar compounds get eluted first and non-polar 
compounds are retained for a longer time. Since most of the drugs and 
pharmaceuticals are polar in nature and not retained for a longer time and 
eluted faster. 
Chromatography is a family of analytical chemistry techniques for the 
separation of mixtures. It involves passing the sample, a mixture that contains the 
analyte, in the "mobile phase", often in a stream of solvent, through the "stationary 
phase." The stationary phase retards the passage of the components of the sample. 
When components pass through the system at different rates they become separated in 
time, like runners in a marathon. Ideally, each component has a characteristic time of 
passage through the system. This is called its "retention time."  
A physical separation method in which the components of a mixture are 
separated by differences in their distribution between two phases, one of which is 
stationary (stationary phase) while the other (mobile phase) moves through it in a 
definite direction. The substances must interact with the stationary phase to be 
retained and separated by it. 
A chromatograph takes a chemical mixture carried by liquid or gas and 
separates it into its component parts as a result of differential distributions of the 
solutes as they flow around or over a stationary liquid or solid phase. Various 
techniques for the separation of complex mixtures rely on the differential affinities of 
substances for a gas or liquid mobile medium and for a stationary adsorbing medium 
through which they pass; such as paper, gelatin, or magnesium silicate gel.  
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Analytical chromatography is used to determine the identity and concentration 
of molecules in a mixture. Preparative chromatography is used to purify larger 
quantities of a molecular species.  
Based on the principle of separation:  
1. Adsorption chromatography: Separation of compounds based on the 
difference in affinity of compounds towards stationary phase. Most 
widely used stationary phase is unmodified silica which allows high 
efficiency and high permeability. The functional group responsible for 
adsorption is silanol group which reacts with sample solutes by 
hydrogen bonding. 
2. Ion exchange chromatography: Separation of compounds based on 
ion exchange of functional groups. In this ion exchange, resins are 
used to separate a mixture of similar charged ions. The retention of the 
ions on the column depends on the ionic strength and PH of the mobile 
phase. Types of ion exchangers include the following:  
1. Polystyrene resins: These allow cross linkage which increases 
the stability of the chain. Higher cross linkage reduces 
swerving, which increases the equilibration time and ultimately 
improves selectivity. 
2. Cellulose and dextran ion exchangers (gels): These possess 
larger pore sizes and low charge densities making them suitable 
for protein separation. 
3. Controlled-pore glass or porous silica: In general, ion 
exchangers favour the binding of ions of higher charge and 
smaller radius. 
Chapter – 1                                                                                                  Introduction 
 
Dept. of Pharmaceutial Analysis              7               J.K.K.Nattraja College of Pharmacy 
3. Ion pair chromatography: In this reverse phase, column is converted 
temporarily into ion exchange column using compounds such as 
pentane or hexane or heptanes or octane with sulphonic acid sodium 
salt, tetra methyl or ethyl ammonium hydroxide. 
4. Size exclusion chromatography (gel permeation chromatography): 
Separation is based on the different molecular size compounds 
separated by using different gels.  
Example: Dextran, agarose, polyacrylamide gels. This technique is 
widely used for the determination of molecular weight of 
polysaccharides. 
5. Affinity chromatography: Separation is based on the affinity of the 
sample with specific stationary phases. 
6. Chiral phase chromatography: Separation of optical isomers using 
chiral stationary phases. 
• Based on elution technique:  
1. Isocratic separation: Same mobile-phase combination is used 
throughout the process of separation. 
2. Gradient separation: Mobile-phase combination of lower polarity or 
elution strength is used followed by gradually increasing the polarity or 
elution strength. 
• Based on scale of operation:  
1. Analytical HPLC  
Example: Analysis of samples (µg). 
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2. Preparative HPLC  
Example: Individual fractions of samples are analysed (mg). (A.H 
Beckett et.al)2 
COMPONENTS OF HPLC SYSTEM: 
Pump 
Pump generates a flow of elute from the solvent reservoir to the system. Most 
pumps used in current LC system generate the flow by back-and forth motion of a 
motor –driven piston. (Reciprocating pumps). Because of this piston motion, it 
produces “pulses”. There have been large system improvements to reduce this 
pulsation and the recent pumps create much less pulse compared to the older ones. 
Recent analysis requires very high sensitivity to quantify a small amount of analytes, 
and thus even a minor change in the flow rate can influence the analysis. Therefore, 
the pumps required for the high sensitivity analysis needs to be highly precise.  
Injector 
            An injector is placed next to the pump. The simplest method is to use a 
syringe, and the sample is introduced to the flow of eluent. Since the precision of LC 
measurement is largely affected by the reproducibility of sample injection, the design 
of injector is an important factor. The most widely used injection method is based on 
sampling loops. The use of auto sampler (auto-injector) system is also widely used 
that allows repeated injections in a set scheduled-timing.  
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Figure1.1 Instumentation of HPLC 
 
Column 
           The separation is performed inside the column; therefore, it can be said that the 
column is the heart of an LC system. The packing material generally used is silica or 
polymer gels. The eluent used for LC varies from acidic to basic solvents. Most 
column housing is made of stainless steel, since stainless is tolerant towards a large 
variety of solvents. However, for the analysis of some analytes such as biomolecules 
and ionic compounds, contact with metals is not desired, thus polyether ether ketone 
(PEEK) column housing is used instead. 
Detector 
Separation of analytes is performed inside the column, Whereas a detector is used 
to observe the obtained separation .The composition of the eluent is consistent when 
no analyte is present .While the presence of analyte changes the composition of the 
eluent. What detector does is to measure these differences. This difference is 
monitored as a form of electronic signal. 
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On-line detectors 
 Refractive index  
 UV/Vis Fixed wave length  
 UV/Vis variable  wave length  
 UV/Vis Diode array 
  Fluorescence 
 Conductivity 
  Mass –Spectrometric (LC/MS) 
 Evaporative light scattering 
Off-line detector 
• FTIR spiral disk monitor requires sample transfer on the germanium disk and 
following scanning in FTIR instrument. 
Recorder 
The change in eluent detected by a detector is in the form of electronic signal, 
and thus it is still not visible to our eyes. Nowadays, computer based data processor 
(integrator) is more common .There are software that are specifically designed for LC 
system. It provides not only data acquisition, but features like peak-fitting, base line 
correction, automatic concentration calculation, molecular weight determination, etc. 
Degasser 
The eluent used for LC analysis may contain gases such as oxygen that are 
non-visible to our eyes. When gas is present in the eluent, this is detected as a noise 
and causes unstable baseline. Generally used method includes sparging (bubbling of 
inert gas), use of aspirator, distillation system, and/or heating and stirring. However, 
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the method is not convenient and also when the solvent is left for a certain time period 
(e.g., during the long analysis), gas will dissolve back gradually. Degasser uses 
special polymers membrane tubing to remove gases. The numerous very small pores 
on the surface of the polymer tube allow the air to go through while preventing any 
liquid to go though the pore. By placing this tubing under low pressure container, it 
created pressure differences inside and outside the tubing (higher inside the tubing). 
This difference let the dissolved gas to move through the pores and remove the gas. 
Compared to classical batch type degassing, the degasser can be used on-line; it is 
more convenient and efficient.  
Column heater 
The LC separation is often largely influenced by the column temperature. Also 
for some analysis, such as sugar and organic acid, better resolutions can be obtained at 
elevated temperature (50~80oC). It is also important to keep stable temperature to 
obtained repeatable results even it is analyzed at around room temperature. There are 
possibilities that small different of temperature causes different separation results. The 
columns are generally kept inside the column oven (column heater).  
(H.H Willard et.al, 1996)3.  
INTRODUCTION TO HPLC METHOD DEVELOPMENT 
Method development has following steps: 
Collect information on sample, define separation goals 
 
Need for special HPLC procedure, sample pretreatment, etc. 
 
Choose detector and detector settings 
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Choose LC method, preliminary run, select best separation conditions 
 
Optimize separation conditions 
 
Check for problems 
  
 
 
 
 
 
 
 
A good method development strategy should require only as many 
experimental runs as are necessary to achieve the desired final result. Finally method 
development should be as simple as possible, and it should allow the use of 
sophisticated tools such as computer modeling.  
The important factors, which are to be taken into account to obtain reliable 
quantitative analysis, are: 
1. Careful sampling and sample preparation. 
2. Appropriate choice of the column. 
3. Choice of the operating conditions to obtain the adequate resolution of the 
mixture. 
4. Reliable performance of the recording and data handling systems. 
Quantitative calibration 
Recover purified material Qualitative method 
Validate method for release to routine laboratory 
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5. Suitable integration/peak height measurement technique. 
6. The mode of calculation best suited for the purpose. 
7. Validation of the development method. 
(Synder  et.al 1983)4.  
Careful sampling and sample preparation 
Before beginning method development, it is need to review what is known 
about the sample in order to define the goals of separation. The sample related 
information that is important is summarized in below.  
Number of compounds present 
Chemical structure 
Molecular weight of compounds 
pka Values of compounds 
UV spectra of compounds 
Concentration range of compounds in samples of interest 
Sample solubility 
The chemical composition of the sample can provide valuable clues for the 
best choice of initial conditions for an HPLC separation. 
Separation Goals 
The goals of HPLC separation need to be specified clearly, which include: 
• The use of HPLC to isolate purified sample components for spectral 
identification or quantitative analysis. 
• It may be necessary to separate all degradants or impurities from a product for 
reliable content assay. 
• In quantitative analysis, the required levels of accuracy and precision should be 
known (a precision of + 1 to 2% is usually achievable). 
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• Whether a signal HPLC procedure is sufficient for a raw material or one or 
more different procedure are desired for formulations. 
• When the number of samples for analysis at one time is greater than 10, a run 
time less than 20 minutes often will be important.      
Sample preparation  
Sample come in various forms: 
• Solution ready for injection. 
• Solutions that require dilution, buffering, addition of and internal standard 
or other volumetric manipulation. 
•  Solids must be dissolved or extracted. 
• Samples that require pretreatment to remove interference and /or protect the 
column or equipment from damage. 
             Most samples for HPLC analysis require weighing and /or volumetric dilution 
before injection. Best results are often obtained when the composition of the sample 
solvents is close to that of the mobile phase since this minimizes baseline upset and 
other problems. Some samples require a partial separation (pretreatment) prior to 
HPLC, because of need to remove interference, concentrate sample analyte or 
eliminate “column killers”.  
             The samples may be of two types, regular or special. The regular samples are 
typical mixtures of small molecules (<2000Da) that can be separated by normal 
starting conditions. Whereas special samples are better separated under customized 
conditions given below. 
Choice of the column 
            The separation of the column in HPLC is somewhat similar to the selection of 
columns in G.C, in the sense that, in the adsorption and partition modes, the   
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separation mechanism is based on inductive forces, dipole-dipole interactions and 
hydrogen bond formation. In case of ion-exchange chromatography, the separation is 
based on the differences in the charge, size of the ions generated by the sample 
molecules and the nature of ionisable group on the stationary phase. In case of size –
exclusion chromatography the selection of the column is based on the molecular 
weight and size of the sample components. Selection of columns based on the method 
is briefly summarized in below. 
Method /Description /Columns Preferred Method 
Reversed – Phase HPLC 
Uses water- organic mobile phase 
 Columns: C18 (ODS), C8, Phenyl, 
trimethylsilyl (TMS), and cyano. 
Iron –pair HPLC 
Uses water – organic mobile phase, a 
buffer to control pH, and an ion –pair 
reagent 
Columns:  C18 , C8, Cyano 
Normal-phase HPLC 
Uses mixtures of organic solvents as 
mobile phase. Columns:  cyano, diol, 
amino, silica 
 
 
First choice for most samples, especially 
neutral or non-ionized compounds that 
dissolve in water-organic mixtures 
 
 
 
 
Acceptable choice for ionic or ionisable 
compounds, especially bases or cations. 
 
Good second choice when reserved-phase 
or ion-pair HPLC is ineffective; first 
choice for lipophilic samples that do not 
dissolve well in water-organic mixtures; 
first choice for mixtures of isomers and 
for preparative HPLC 
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Optimization of HPLC method  
During the optimization stage, the initial sets of conditions that have evolved 
from the first stages of development are improved or maximized in terms of 
resolution and peak shape, plate  counts asymmetry, capacity factor, elution time, 
detection limits, limit of quantitation and overall ability to quantify the specific 
analyte of interest. Optimization of a method can follow either of two general 
approaches: 
 Manual 
 Computer driven 
The manual approach involves varying one experimental variable at a time, while 
holding all other constant and recording changes in response. The variables might 
include flow rate, mobile or stationary phase composition, temperature, detection 
wavelength and pH. This approach to system is slow, time consuming and potentially 
expensive. However, it may provide a much better understanding of the principles and 
theory involved and of interactions of the variables.  
         In the second approach, computer driven automated method development, 
efficiency is optimized while experimental input is minimized. This approach reduce 
the time, energy and cost of all instrumental method development. 
The various parameters that include to be optimized during method development are  
A. Selection of mode of separation. 
B. Selection of stationary phase. 
C. Selection of mobile phase. 
D. Selection of detector. 
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Selection of mode of separation  
In reverse phase mode, the mobile phase is comparatively more polar than the 
stationary phase. For the separation of polar or moderately polar compounds, the most 
preferred mode is reverse phase. The nature of the analyte is the primary factor in the 
selection of the mode of separation. A second factor is the nature of the matrix.  
Selection of stationary phase 
             Selection of the column is the first and the most important step in method 
development. The appropriate choice of separation column indicates three different 
approaches. 
 Selection of separation 
 The particle size and nature of the column packing 
 The physical parameters of the column i.e. the length and the diameter some 
of the important parameters considered while selecting chromatographic 
columns are 
 Length and diameter of the column 
 Packing material 
 Shape of the particles 
 Size of the  particles 
 % of carbon loading 
 Pore volume 
 Surface area  
 Reproducibility and reliability 
 End capping 
In this case, the column selected had a particle size of 5µm and an internal 
diameter of 4.6mm.The column is selected depending on the nature of the solute and 
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the information about the analyte. Reversed phase mode of chromatography facilities 
a wide range of columns like dimethyl silane (C2), butysilane (C4), octylsilane (C8),  
Octadecyslane (C18), base deactivated silane (C18), BDS phenyl, Cyanopropyl (CN), 
nitro, amino etc. silica based columns with different cross linking’s in the increasing 
order of polarity are as follows:  
 
<………………..Non-polar………….moderately polar…………..polar……..> 
                             C18 < C8 < C6 < Phenyl < Amino < Cyano < Silica 
 
           C18 was chosen for this study since it is most retentive one. The sample 
manipulation becomes easier with this type of column. Generally longer columns 
provide better separation due to higher the theoretical plate numbers. Columns with 
5µm particle size give the best compromise of efficiency. 
      Peak shape is equally important in method development. Columns that provide 
symmetrical peaks are always preferred while peaks with poor asymmetry can result 
in, 
• Inaccurate plate number and resolution measurement 
• Imprecise quantitation 
• Degraded and undetected minor bands in the peaks tail 
• Poor retention reproducibility 
                 A useful and practical measurement of peak shape is peak asymmetry 
factor and peak tailing factor. Peak asymmetry is measured at 10% of full peak height 
and peak tailing factor at 5%. Reproducibility of retention times and capacity factor is 
important for developing a rugged and repeatable method.  
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           A column which gives separation of all the impurities and degradants from 
each other and from analyte peak and which is rugged for variation in mobile phase 
shall be selected. 
Selection of mobile phase 
          The primary objective in selection and optimization of mobile phase is to 
achieve optimum separation of all the individual impurities and degradants from each 
other and from analyte peak. 
          In liquid chromatography, the solute retention is governed by the solute 
distribution factor, which reflects the different interactions of the solute – stationary 
phase, solute-mobile phase, and mobile phase-stationary phase. For a given stationary 
phase, the nature and the composition of which has to be judiciously selected in order 
to get appropriate and required solute retention. The mobile phase has to be adapted in 
terms of elution strength (solute retention) and solvent selectivity (solute 
separation).Solvent polarity is the key word in the chromatographic separations since 
a polar mobile phase will give rise to low solute retention in normal phase and high 
solute retention in reverse phase LC. The selectivity will be particularly altered if the 
buffer pH is close to the pKa of the analytes. The following are the parameters, which 
shall be taken into consideration while selecting and optimizing the mobile phase. 
 Buffer 
 pH of the buffer 
 Mobile phase composition 
Buffers if any and its strength  
             Buffer and its strength play an important role in deciding the peak symmetries 
and separations. Some of the most commonly employed buffers are 
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 Phosphate buffers prepared using salts like KH2PO4, K2HPO4, NaH2PO4, and 
Na2HPO4
.
 
 Phosphoric acid buffers prepared using H3PO4. 
 Acetate buffers-ammonium acetate, sodium acetate etc. 
 Acetic acid buffers prepared using CH2COOH. 
            The retention also depends on the molar strengths of the buffer-molar strength 
is increasingly proportional to retention times. The strength of the buffer can be 
increasing, if necessary to achieve the required separations. The solvent strength is a 
measure of its ability to pull analyte from the column. It is generally controlled by the 
concentration of the solvent with the highest strength. The useful pH range for 
columns is 2 to 8, since siloxane linkages are cleaved below pH-2 while at pH values 
above eight, silica may dissolve. 
Mobile phase composition  
             Most chromatographic separations can be achieved by choosing the optimum 
mobile phase composition. This is due to the fact that fairly large amount of 
selectively can be achieved by choosing the qualitative and quantitative composition 
of aqueous and organic portions. Most widely used solvents in reverse phase 
chromatography are methanol and Acetonitrile. Experiments should be conducted 
with mobile phases having buffers with different pH and different organic phases to 
check for the best separations of analyte peak. A mobile phase which gives separation 
of analyte peak  
and which is rugged for variation of both aqueous and organic phase by at least + 
0.2% of the selected mobile phase composition should be used.  
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Selection of Detector 
            The detector was chosen depending upon some characteristic property of the 
analyte like UV absorbance, florescence, conductance, oxidation, reduction etc. The 
characteristics that are to be fulfilled by a detector to be used in HPLC determination 
are, 
 High sensitivity facilitating trace analysis 
 Negligible baseline noise to facilitate lower detection. 
 Large linear dynamic range. 
 Low dead volume. 
 Inexpensive to purchase and operate. 
            Pharmaceutical ingredients do not absorb all UV light equally, so that 
selection of detection wavelength is important. An understanding of the UV light 
absorptive properties of the organic impurities and the active pharmaceutical 
ingredient is very helpful. For the greatest sensitivity ƛmax should be used. Ultra 
violet wavelengths below 200nm should be avoided because detector noise increases 
in this region. Higher wave lengths give greater selectivity.  
Performance calculations 
             Carrying out system suitability experiment does the performance calculations. 
System suitability experiments can be defined as tests to ensure that the method can 
generate results of acceptable accuracy and precision. The requirements for system 
suitability are usually developed after method development and validations have been 
completed. The criteria selected will be based on the actual performance of the 
method as determined during its validation. For example, if sample retention times 
form part of the system suitability criteria, their variation SD can be determined 
during validation. 
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        System suitability might then require that retention times fall within a + 3 SD 
range during routine performance of the method. 
        The USP (2000)5 defines parameters that can be used to determine system 
suitability prior to analysis include plate number(n), tailing factor(T), resolution(Rs) 
and relative standard deviation (RSD) of peak height or peak area for respective 
injections. 
        The RSD of peak height or area of five injections of a standard solution is 
normally accepted as one of the standard criteria .For assay method of a major 
component, the RSD should typically be less than 1% for these five respective 
injections.  
    The plate number and / or tailing factor are used if the run contains only one peak. 
For chromatographic separations with more than one peak, such as an internal 
standard assay or an impurity method expected to contain many peaks, some measure 
of separations such as Rs is recommended. Reproducibility of tR  or k value for a 
specific compound also defines system performance. 
         The column performance can be defined in terms of column plate number. As 
the plate count is more the column is more efficient. 
METHOD VALIDATION  
         The word “Validation’’ means “Assessment’’ of validity or action of proving 
effectiveness. 
Definition 
ICH6 defines validation as “establish the documented evidence which provides a high 
degree of assurance that a specific process will consistently produce a product of 
predetermined specifications and quantity attributes.’’ 
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              Method validation is the process to confirm that the analytical procedure 
employed for a specific test is suitable for its intended use. Method needs to be 
validated or revalidated. 
 Before their introduction into routine use 
 Whenever the conditions change for which the method has been validated, 
e.g., instrument with different characteristics 
 Whenever the method is changed, and the change is outside the original scope 
of the method. 
 Purpose of validation 
 Enable the scientists to communication scientifically and effectively on 
technical matter. 
 Setting the standards of evaluation procedures for checking compliance and 
taking remedial action. 
 Economic: Reduction in cost associated with process sampling and testing. 
 As quality of the product cannot always be assured by routine quality control 
because of testing of statistically insignificant number of samples. 
 Retrospective validation is useful for trend comparison of results compliance 
to CGMP/CGLP. 
 Closure interaction with pharmacopoeial forum to address analytical 
problems. 
 International pharmacopoeial harmonization particularly in respect of 
impurities determination and their limits. 
           Method validation is completed to ensure that an analytical methodology is 
accurate, specific, reproducible and rugged over the specified range that an analyte 
will be analyzed. Method validation provides an assurance of reliability during normal 
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use, and is sometime referred to as “the process of providing documented evidence 
that the method does what it is intended to do’’. 
For method validation, these specifications are listed in USP chapter <1225>, and can 
be referred to as the “eight steps of method validation”. As shown in figure below. 
These terms are referred to as “analytical performance parameters’’ Or sometimes as 
“analytical figures of merit.’’  
In response to this situation, one of the first harmonization projects taken up by the 
ICH was the development of a guideline on the “Validation of Analytical Methods” 
Definitions and Terminology. “ICH divided the “Validation characteristics” 
somewhat differently, as outlined in Figure below 
The USP Eight steps of method validation 
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ICH Method Validation Parameters 
Method validation parameters 
           The developed methods were validated by following steps: 
A. Accuracy 
         It is defined as closeness of agreement between the actual (true) value and mean 
analytical value obtained by applying a test method number of times. Spike and 
recovery studies are performed to measure accuracy; a known sample is added to the 
excipients and the actual drug value is compared to the value found by the assay. 
Accuracy is expressed as the bias or the % error between the observed value and the 
true value (assay value/actual value x 100 %.) 
          The accuracy is acceptable if the difference between the true value and mean 
measured value does not exceed the RSD values obtained for repeatability of the 
method. The parameter provides information about the recovery of the drug from 
sample and effect of matrix, as recoveries are likely to be excessive as well as 
deficient. 
Repeatability is the result of the method operating over a short time interval under 
the same conditions (or) is the % RSD of multiple determinations of a single sample 
in a single test run (intra-assay precision). It should be determined from a minimum of 
nine determinations covering the specified range of the procedure (for example, three 
levels three repetitions each) or from a minimum of six determinations at 100% of the 
test or target concentration. 
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Intermediate precision is the results from within lab variations due to random events 
such as different days, analysts, equipment, etc. In determining intermediate 
precision, experimental design should be employed so that the effects (if any) of the  
  individual variables can be monitored (or) intermediate precision (also called inter-
assay precision) measure the % RSD for multiple determinations of a single sample, 
controls and reagents analyzed in several assay  runs in the same laboratory.  
Reproducibility 
It refers to the precision between laboratories usually in collaborative studies 
and not directly relevant to assay validation in a manufacturing facility. 
Documentation in support of precision studies should include the standard deviation, 
relative standard deviation, coefficient of variation, and the confidence interval. 
 Specificity 
              It is the ability of an analytical method to assess unequivocally the analyte of 
interest in the presence of components that may be expected to be present, such as 
impurities, degradation products and matrix components. It is not possible to 
demonstrate that an analytical procedure is specific for a particular analyte. In such 
case a combination of two or more analytical procedure is recommended to achieve 
the necessary level of discrimination. Lack of specificity of an individual analytical 
procedure may be compensated by other supporting analytical procedures or tests. 
               In case of the assay, demonstration of specificity requires that the procedure 
is unaffected by the presence of impurities or excipients. In practice, this can be done 
by spiking the drug substances or product with appropriate levels of impurities or 
excipients and demonstrating that the assay is unaffected by the presence of these 
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extraneous materials. If the degradation product impurity standards are unavailable, 
specificity may be demonstrated by comparing the test results of samples containing 
impurities or degradation products to a second well-characterized procedure e.g., 
pharmacopoeia method or other validated analytical procedure (independent 
procedure). These comparisons should include samples stored under relevant stress 
conditions (e.g. light, heat humidity, acid/base hydrolysis, oxidation.ect.) 
Limit of Detection 
             The limit of detection (LOD) is defined as the lowest concentration of an 
analyte in a sample that can be detected, not quantitated. It is a limit test that specifies 
whether or not an analyte is above or below a certain value. It is expressed as a 
concentration at a specified signal-to- noise ratio, usually two –or three-to-one. The 
ICH has recognized the signal-to-noise ratio convention, but also lists two other   
options to determine LOD: visual non-instrumental methods and a means of 
calculating the LOD. The method used to determine LOD should be documented and 
supported, and an appropriate number of samples should be analyzed at the limit to 
validate the level.          
Limit of Quantitation 
              The limit of quantitation (LOQ) is defined as the lowest concentration of an 
analyte in a sample that can be determined with acceptable precision and accuracy 
under the stated operational conditions of the method. That is, as the LOQ 
concentration level decreases, the precision increases. If better precision is required, a 
higher concentration must be reported for LOQ. 
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Linearity 
               It is ability of an assay to obtain test results, which are directly proportional 
to the concentration of an analyte in the sample. The determination of linearity will 
Identify the range of the analytical assay. It can be measured as slope of the regression 
line and its variance or as the coefficient of determination (R2) and correlation 
coefficient(R). 
Range 
            Range is the interval between the upper and the lower levels of analyte 
(inclusive) that have been demonstrated to be determined with precision, accuracy and 
linearity using the method as written. If the relationship between response and 
concentration is the linear, the range may be estimated by means of a calibration 
curve. 
           The range is normally expressed in the same units as the test results obtained 
by the method. The ICH guidelines specify a minimum of five concentration levels, 
along with certain minimum specified ranges. For assay the minimum specified range 
is from 80-120% of the target concentration. For an impurity test, the minimum range 
from the reporting level of each impurity, to 120% of the specification.  (For toxic or 
more potent impurities, the range should be commensurate with the controlled level).  
 Ruggedness 
               Ruggedness, according to the USP, is the degree of reproducibility of the 
results obtained under a variety of conditions, expressed as %RSD. The ruggedness of 
an analytical method is the degree of reproducibility of test results obtained by the 
analysis of the same samples under a variety of conditions such as different 
laboratories, different analysts, different instruments, different lot of reagents, 
different elapsed assay times, different assay temperatures different days, etc.  
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 Robustness 
               ICH defines robustness as a measure of the method’s capability to remain 
unaffected by small, but deliberate variations in method parameters. Robustness can 
be partly assured by good system suitability specifications. The evaluation of 
robustness should be considered during the development phase and depends on the 
type of procedure under study. It should show the reliability of an analysis with 
respect to deliberate variations in method parameters. If the results of a method or 
other measurements are susceptible to variations in method parameters, these 
parameters should be adequately controlled and a precautionary statement included in 
the method documentation. One consequence of the evaluation of robustness should 
be that a series of system suitability parameters (e.g., resolution test) is established to 
ensure that the validity of the analytical procedure is maintained whenever used. 
 System Suitability Test  
            System suitability test is commonly used to verity resolution, column 
efficiency and repeatability of the chromatographic system to ensure its adequacy for 
a particular analysis. According to the United States pharmacopoeia (USP) and the 
International Conference on Harmonization (ICH), SST is an integral part of many 
analytical procedure. 
            Primary SST parameters are most important as they indicate system 
specificity, precision and column stability. Other parameter include capacity factor 
(K) and signal to noise ratio(S/N) for impurity peaks. 
             The USP chromatography general chapter states “System suitability test are 
an integral part of gas and liquid chromatographic methods. They are used to verify 
that the resolution and reproducibility of the chromatographic system are adequate for 
the analysis to be done. The tests are based on the concept that the equipment, 
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electronics, analytical operations and samples to be analyzed constitute an integral 
system can be evaluated as such.” (USP 38-NF 31, 621 – Chromatography) 5 
 
INTERPRETASTION OF CHROMATOGRAMS 
              Figure below represents a typical chromatographic separation of two 
substances, 1 and 2, where t1 and t2 are the respective retention times; and h, h/2, and 
Wh/2 are the height, the half – height, and the width at half-height, respectively, for 
peak1. W1 and W2 are the respective widths of peaks 1 and 2 at the base line. Air 
peaks are a feature of gas chromatograms and correspond to the solvent front in liquid 
chromatography. 
Figure 1.2 Diagrammatic representation of Interpretation of chromatogram 
 
 
 
 
 
 
 
 
                Chromatography retention times are characteristic of the compounds they 
represent but are not unique. Coincidence of retention times of a test and a reference 
substance can be used as a feature in construction of an identity profile but is 
insufficient on its own to establish identity. Absolute retention times of a given 
compound vary from one chromatogram to the next. 
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Relative Retention times: 
 Relative retention time is calculated by the equation Rr = t2/t1  
t1 = Retention time of test. 
t2 = Retention time of reference substance, determined under identical experimental 
conditions on the same column.  
Relative Retention:  
  
t
2
 – t
M 
To calculate the relative retention (r) = --------- 
 t1-tM 
 
Where  tM is the retention time of the non-retained marker.  
Resolution  
               The resolution R is a function of column efficiency, N and is specified to 
ensure that closely eluting compounds are resolved from each other, to establish the 
general resolving power of the system, and to ensure that internal standards are 
resolved from the drug. 
Figure1.3 Resolution 
 
 
R is determined by the equation:  
R=
()       Or 
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                    2(t2-t2)       
R =    __________________ 
          1.70 (W1, h/2 + W2, h/2) 
 
t2 and t1 are the retention times of the components.  
 W2 and W1 are the corresponding width at the bases of the peaks obtained by 
extrapolating the relatively straight sides of the peaks to the base line. 
W1h/2 and W2h/2 are the corresponding peak width at half-height. 
Resolution  
               1.18(tR2 – tR1)      
R =  _______________ 
             (Wh1 + W h2) 
Where, t R2 > tR1 
tR2 and tR1 = Retention times or distances along the baseline from the point of 
injection to the perpendiculars dropped from the maxima of two adjacent peak 
Wh1and Wh2 = peak width at half height.  
Theoretical Plates  
               Column efficiency also may be specified as system suitability requirements, 
especially if there is only one park of interest in the chromatograms. The number of 
the theoretical plates, N, is a measure of column efficiency. It is calculated by the 
equation. 
N= 16 [t/w] 2 or    N= 5.54 [t/w1/2]2 
t = Retention time of the substance. 
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w = width of the peak at its base, obtained by extrapolating the relatively straight 
sides of the peak to the baseline.  
W1/2 = Peak width at half-height. 
 Precision: 
                Precision a measure of either degree of reproducibility or of repeatability  is 
determined by making replicate injections of standard preparation and calculating 
relative standard deviation. Unless otherwise specified in the individual monograph, 
data from five replicate injections of the standard preparation are used to calculate the 
relative standard deviations (SR), if the requirement is 2.0% or less; data from six 
replicate injections are used if the relative standard deviation requirement is more than 
2.0%. 
Relative Standard Deviation in percentage. 
SR (%) = 
 [∑ ()

 ] 
x = Arithmetic mean of the set. 
xi = An individual measurement in a set of N measurements. 
N= Number of individuals values 
Tailing Factor (or) Symmetry factor  
               Tailing factor, T, a measure of peak symmetry, is unity for perfectly 
symmetrical peaks and its value increases as tailing factor is pronounced (Fig 1). In 
some cases values less tan unity may be observed. As peak asymmetry increases, 
integration and hence precision becomes less reliable. 
Tailing factor, T = .  
W0.05 = Width of peak at 5% height. 
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F = Distance from the peak maximum to the leading edge of the peak, the distance is 
being measured at a point 5% of the peak height from baseline. 
Capacity Factor (Mass distribution ratio): 
          Capacity factor k’ of a sample component is a measure of the degree which that 
component is retained by the column relative to an unretained component  
           Capacity factor is k, =  !"!  
tr – is the elution time of retained component and 
t0 – is the elution time of the unretained sample. 
Signal to Noise Ratio:  
            S/N = ##  
Where, 
H  = Height of the peak corresponding to the component concerned, in the 
chromatogram obtained with the prescribed reference solution, measured from the 
maximum of the peak to the extrapolated baseline of the signal observed over a 
distance equal to 20 times the width at half-height.  
h = Range of the background noise in a chromatogram obtained after injection 
or application of a blank, observed over a distance equal to 20 times the width at half-
height of the peak in the chromatogram obtained with the prescribed reference 
solution and, if possible, situated equally around the place where this peak would be 
found. 
Peak to Valley ratio 
          The peak-to-valley ratio (p/v) may be employed as a system suitability 
requirement in a test for related substances when baseline separation between 2 peaks 
is not reached  
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P/v = #$#% 
Hp = Height above the extrapolated baseline of the minor peak, 
Hv = Height above the extrapolated baseline at the lowest point of the curve 
separating the minor and major peaks. (ICH 2005)6 
 System Suitability Parameters and Recommendations: 
Parameter Recommendation 
Capacity Factor (k’) The peak should be well-resolved from the other peaks and 
the void volume, generally k’>2.0 
Repeatability RSD, ≤1% for N≥5 is desirable 
Relative retention  Not essential as long as the resolution is stated  
Resolution Rs of >2 between the peak of interest and the closed eluting 
Tailing Factor (T) T of ≤2 
Theoretical Plates (N) In general should be > 2000 
 
STATISTICAL PARAMETERS 
Linear regression:  
         Once a linear relationship has been shown to have a high probability by the 
value of the correlation coefficient ‘r’, then the best straight line through the data 
points has to be estimated. This can often be done be done by visual inspection of the 
calibration graph, but in many cases it is far more sensible to evaluate the best straight 
line by linear regression (the method of least squares). 
The equation of straight line is y = mx + c 
Where, y the dependent variable is plotted as result of changing x, the independent 
variable.  
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To obtain the regression line ‘y on x’ the slope ‘m’ of the line and the intercept ‘c’ on 
the y axis are given by the following equation. 
m= & ∑ '((∑ ')(∑ ()& ∑ '(∑ ')     and       c=   & ∑ ( ∑ '(∑ ')(∑ ()& ∑ '(∑ ')  
Correlation coefficient: 
When the changes in one variable are associated or followed by changes in the order 
it is called correlation. To establish whether there is a liner relationship between two 
variables x1 and y1, use Pearson’s correlation coefficient r. 
r=
 ∑ )
*
∑ )
*
{[ ∑ )
(∑ )
)][ ∑ *
(∑ *
)]}
 ⁄  
Where n is the number of data points. 
             The value of r must lie between +1 and -1, the nearer it is to +1, the greater 
the probability that a define linear relationship exists between the variables x and y, 
values close to +1 indicate positive correlation and values close to -1, indicate 
negative correlation values of ‘r’ that tend towards zero indicate that x and y are not 
linearly related (they made be related in a non-linear fashion). 
 
Standard deviation: 
               The standard deviation measures the spread f the data about the mean value. 
It is commonly used in statics as a measure of precision statics as a measure of 
Precision and is more meaningful than is the average and is expressed mathematically 
as.  
S = 23 (Xi − x)8N − 1
  
Where, 
S is the standard deviation. 
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If N is large (50 or more) then of course it is immaterial whether the term in the  
Denomination is N-1 or N 
   Σ = sum 
X = observed values 
;= Mean or arithmetic average = ΣX/N 
X - ; = deviation of a value from the mean  
N = Number of observations 
 
 
Percentage relative standard deviation 
    It is also known as coefficient of variation CV. It is defined as the standard 
deviation (S.D) expressed as the percentage of mean. 
  CV or % RSD = <.=  x 100 
Where, S.D = Standard deviation, 
               ; = Mean or arthimetic average. 
The variance is defined as S2 and is more important in statistics than S itself. 
However, the latter is much more commonly used with chemical data.  
Standard Error of mean:  
        Standard error of mean can be defined as the value obtained by division of 
standard deviation by square root of number of observation. It is mathematically 
expressed as  
          S.E = <.=√   
Where, n = number of observations. 
S.D = Standard Deviation  
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2. LITERATURE REVIEW 
1. R Arun et al13 described the development and validation of a simultaneous 
HPLC-UV method for the estimation of Artemether and Lumefantrine in 
fixed-dose combination tablets. The method showed to be linear (r2 > 0.999), 
precise (RSD <0.43%), accurate (recovery of 99.81% for Artemether and 
99.54% for Lumefantrine), specific and robust. Three batches of Artemether 
and Lumefantrine tablets were assayed by the validated method. The 
Artemether contents in the tablets varied from 99.30 to 99.33%, while 
Lumefantrine contents were 99.65 to 99.66%. 
  
2. S Sharma et al14 had done estimation of Lumefantrine in pharmaceutical 
dosage forms, in that they described three simple, rapid, accurate, precise and 
cost-effective methods, I; formation and solving of simultaneous equation 
method, II; absorbance ratio method, III; Dual Wavelength Method have been 
developed for simultaneous estimation of Lumefantrine in tablet dosage form. 
Beer’s law was obeyed in concentration range 5-35 µg/ml for Lumefantrine 
for all the proposed methods. The sampling wavelengths for methods I, II and 
III, selected for both the drugs were 252nm, 268nm and 296nm, on trial and 
error basis using0.01 N NaOH solutions as solvent. For methods I, II, III seven 
mixed standards solutions with concentration of Lumefantrine in the µg/ml of 
5:35, 10:30, 15:25, 20:20, 25:15, 30:10 and 35:5, were prepared by diluting 
appropriate volumes of standard stock solutions for all proposed three 
methods. Results of analysis for six methods were tested and validated for 
various parameters according to ICH guidelines. 
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3. Mohamed Aly Amin Ahmed Ibrahim et al 15 developed a HPLC Method and 
did Validation for Determination of Lumefantrine in Pharmaceutical Dosage 
Forms, it described a simple, precise and rapid HPLC method was developed 
for estimation of Lumefantrine in pure and pharmaceutical dosage forms. The 
chromatographic separation was conducted on Shimadzu (Prominence LC 20 
UFLC XR) connected with PDA detector; using column C18; Waters, (300 x 
3.9 mm, 10 µm). The isocratic mobile phase consisted of ion pair reagent: 
Acetonitrile in ratio of (35: 65 v/v). Ion pair reagent is composed of 5.65 g of 
sodium hexane sulfonate and 2.75 g of sodium dihydrogen phosphate in 900 ml 
of water, adjusted to pH 2.3 with Phosphoric acid 85%, diluted to 1000 ml with 
water and filtered through 0.45 µm filter. The mobile phase was delivered to 
the system at a flow rate of 2 ml/min. An injection volume of 20 µl was used 
for Lumefantrine. The detection was carried out by PDA detector 342 nm. The 
calibration2 curve of Lumefantrine in mobile phase was linear with correlation 
coefficient (r) = 0.99946; over a concentration range of 60 – 1200 mg/l; with a 
retention time of 3.686 minutes. The percentage recovery of Lumefantrine was 
100.029%. The relative standard deviation (RSD) was found to be less than 2. 
The proposed method was validated and successfully applied for determination 
of Lumefantrine in tablet dosage form. 
 
4. Mohamed Aly Amin Ahmed Ibrahim et al 16  developed a HPLC Method D 
and did Validation for Determination of Artemether in Pharmaceutical Dosage 
Forms, it described a fast, precise and simple HPLC method was developed 
for estimation of Artemether in pure and pharmaceutical dosage forms. The 
chromatographic separation was conducted on Shimadzu (Prominence LC 20 
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HPLC) connected with Detector is ELSD with nitrogen pressure =360 Kpa; 
and temp = 37°C; Gain = 7; using column C18; Waters µ Bondapak, (300×3.9 
mm, 10 µm). The isocratic mobile phase consisted of Acetonitrile: water in 
ratio of (90: 10, v/v). The mobile phase was delivered to the system at a flow 
rate of 1.5 ml/min. An injection volume of 20 µl was used for Artemether. 
Column Temperature was 37°C. The detection was carried out using ELSD 
detector. The calibration curve of Artemether in mobile phase was linear with 
correlation coefficient (r2) of 0.9987; over a concentration range of 1100–
2000 mg/L; with a retention time of2.52 min. The percentage recovery of 
Artemether was 96.34%. The relative standard deviation (RSD) was found to 
be less than 2. The proposed method was validated and successfully applied 
for determination of Artemether in tablet dosage form. 
 
5. T.M. Kalyankar et al17 had done a simple, rapid, precise and accurate 
reversed phase high performance liquid chromatographic method has been 
developed for the simultaneous determination of Artemether in combination 
with Lumefantrine. This method uses a Hypersil ODS C18 
(250mm  ~4.6mm ~5µ particle Size) analytical column, a mobile phase of 
methanol: 0.05 % trifluroacetic acid with triethylamine buffer pH 2.8 adjusted 
with ortho phosphoric acid in ratio (80:20 v/v). The instrumental settings are a 
flow rate of 1.5 ml/min and PDA detector wavelength at 210 nm. The 
retention times for Artemether and Lumefantrine are 6.15 min and 11.31min, 
respectively. The method is validated and shown to be linear. The linearity 
range for Artemether and Lumefantrine are 20-120 & 120-720 µg/ml 
respectively. The Percentage recovery for Artemether and Lumefantrine are 
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ranged between 99.50–101.16 and99.78–101.21 respectively. The correlation 
coefficients of Artemether and Lumefantrine are 0.999, and 
0.999,respectively. The relative standard deviation for six replicates is always 
less than 2%. The Statistical analysis proves that the method is suitable for 
analysis of Artemether and Lumefantrine as a bulk drug and in pharmaceutical 
formulation without any interference from the excipients.      
 
6. J Sunil et al18 had done a simple and precise HPLC method was developed for 
the estimation of Artemether and Lumefantrine in pure and pharmaceutical 
dosage forms. The quantification was carried out using symmetry C18, 250 x 
4.6 mm, i.d, 5µm particle size in isocratic mode, with mobile phase 
compressing of buffer and Acetonitrile in the ratio of 40:60 (v/v), pH 3 ± 0.5. 
The flow rate was 1.5 ml/min and the detection was carried out by UV 
detector dual i.e, 210 and 303 nm. The retention times were 13.887 and 7.218 
minutes for Artemether and Lumefantrine, respectively. The percentage 
recovery was found to be 98.87 and 99.78 % for Artemether and 
Lumefantrine; respectively. The method was validated by evaluation of 
different parameters.  
 
7. M Laxmi et al19 had done analytical method development and validation of 
Artemether in bulk drug, the method was found to be linear in the 
concentration range of 100-600 µg/ml, in the linearity study regression 
equation was found to be y = 0.199x – 1.133 & correlation coefficient was 
found to be 0.999. This method was Rugged and Robust in different testing 
criteria, LOD and LOQ were found to be 23.037µg/ml, 69.809µg/ml 
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respectively. Accuracy study was done in 3 different concentration level i.e 
50, 100, 150% & % recovery of the method was found to be 99.4%, 100.4%, 
99.7% respectively in 3 different levels & mean recovery was 99.8%, so 
method was accurate.  A Simple and precise HPLC method was developed for 
the estimation of Artemether and Lumefantrine in pure and pharmaceutical 
dosage forms. The quantification was carried out using symmetry C18, 250 x 
4.6 mm, i.d, 5µm particle size in isocratic mode, with mobile phase 
compressing of buffer and Acetonitrile in the ratio of 40:60 (v/v), pH 3 ± 0.5. 
The flow rate was 1.5 ml/min and the detection was carried out by UV 
detector dual i.e, 210 and 303 nm. The retention times were 13.887 and 7.218 
minutes for Artemether and Lumefantrine, respectively. The percentage 
recovery was found to be 98.87 and 99.78 % for Artemether and 
Lumefantrine; respectively. The method was validated by evaluation of 
different parameters. 
 
8. R Arun et al20 had done development of analytical method for Lumefantrine 
by UV spectrophotometry, A Simple, sensitive, specific, spectrophotometric 
method has been developed for the detection of Lumefantrine in pure form and 
Pharmaceutical formulations. The optimum condition for the analysis of the 
drug was established. Lumefantrine exhibiting absorption at 234nm and 
obeyed beers law in the concentration range 8 to 16µg/ml. The lower limit of 
detection was found to be 4.3×10-2 and the limit of quantification to be 13.2 
×10-2. The regression equation was y = 0.065x + 0.02. The precision of the 
method was found to be 480.96mg at 234nm against the label claim of 480mg 
. The sample solution was stable up to 24 hours. The assay results were found 
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to be in good agreement with label claim. The proposed method was simple 
sensitive, precise, quick and useful for routine quality control. 
 
9. Isabella da Costa Ce´ sar et al21 did a  simultaneous determination of 
Artemether and Lumefantrine in fixed dose combination tablets by HPLC with 
UV detection, this paper described the development and validation of a HPLC-
UV method (210 nm) for the simultaneous quantitation of Artemether and 
Lumefantrine in fixed dose combination tablets. The method showed to be 
linear (r2 > 0.99), precise (R.S.D. < 2.0%), accurate (recovery of 101.07% for 
Artemether and 101.58%for Lumefantrine), specific and robust. Four batches 
of Artemether–Lumefantrine tablets were assayed by the validated method. 
The Artemether contents in the tablets varied from 98.61% to 103.35%, while 
Lumefantrine contents were 97.92–100.48%.  
 
10. B Nasir et al22 had done a new HPLC  method for the determination of  
Artemether  in injections, this new economical HPLC method has been 
developed for the estimation of Artemether in injections to reduce the cost of 
estimation. Previously, one HPLC method is available in European 
Pharmacopoeia for the estimation of Artemether but it is costly due to high 
price of Acetonitrile. Present study replaced Acetonitrile with methanol and 
showed that new method remained as specific, linear, accurate and precise as 
previous. 
 
11. Naveen S Kotur et al23 had done Analytical Method Development and 
Validation for Estimation of Lumefantrine in Pharmaceutical Dosage Forms 
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by HPLC A Simple, rapid, sensitive, precise, accurate, stability indicating and 
reproducible of High Performance Liquid chromatography(HPLC) method has 
been developed for the estimation of Lumefantrine in pharmaceutical Tablet 
dosage forms. The HPLC method was carried out using Waters Symmetry 
C18 (250 X 4.5 mm) analytical column with maintained the column oven 
temperature 35 °C and isocratic pump mode. The mobile phase compressing 
of water, acetonitrile and glacial acetic acid in the ratio of 48: 52: 1, v/v/v with 
delivered the flow rate of 1.2mL /min and the detected the Lumefantrine at 
276 nm from PDA detector. The retention time of Lumefantrine was 4.65 
minutes. This method has been validated as per ICH guidelines and the 
validation data showed that the assay is sensitive, specific and reproducible for 
the determination of Lumefantrine in the dosage form. The method is linear 
from 10µgmL-1 to100µgmL-1 and linear correlation coefficient (R2) was 
more than 0.9990. The accuracy of the method by recovery was found 
between99.44 and 100.14 %. Mean inter and intraday assay relative standard 
deviation (RSD) were less than 1.0%. The proposed method provided an 
accurate and precise analysis of Lumefantrine in its Pharmaceutical dosage 
form. 
 
12. Gupta N.K et al24 had done simultaneous determination of Artemether and 
Lumefantrine by RP-HPLC method development in pharmaceutical tablet 
dosage form, the chromatographic analysis was performed by Hypersil BDS 
C18, 250 × 4.6 mm, 5 µ particle size with mobile phase consisting of buffer 
and Acetonitrile in the ratio of 50:50v/v, orthophosphoric acid used as buffer 
(pH 3.0 + 0.6), at a flow rate of 1.5 ml/min and eluents monitored at 215nm. 
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The method was validated for linearity, accuracy, precision, robustness and 
application for assay as per ICH guidelines. The retention times of Artemether 
and Lumefantrine were 2.464 and 6.236 min, respectively. The calibration 
curves of peak area versus concentration, which was linear from 4-24µg/ml for 
Artemether and 24-144µg/ml for Lumefantrine, had regression coefficient (r2) 
greater than 0.999. The method had the requisite accuracy, precision, and 
robustness for simultaneous determination of Artemether and Lumefantrine in 
tablets. The proposed method is simple, economical, accurate and precise, and 
could be successfully employed in routine quality control for the simultaneous 
analysis of Artemether and Lumefantrine in tablets. 
 
13. B Sridhar et al25 had done a validated reverse phase HPLC method for the 
simultaneous estimation of Artemether and Lumefantrine in pharmaceutical 
dosage forms, a simple, sensitive and precise reverse phase high performance 
liquid chromatographic method has been developed for the simultaneous 
estimation of Artemether and Lumefantrine in pharmaceutical dosage forms. 
The mobile phase consisted of Acetonitrile: buffer (0.1% v/v ortho phosphoric 
acid, PH – 3) in the ratio of 60:40 v/v delivered at a flow rate of 1.5 ml / min 
and wavelength of detection at 303 nm. The retention times of Artemether and 
Lumefantrine were 13.888 min and 7.207 min respectively. The developed 
method was validated according to ICH guidelines. The proposed method can 
be used for determination of these drugs in combined dosage forms. 
 
14. P Umapathi et al26 had done development and Validation of a Dissolution 
Test Method for Artemether and Lumefantrine in Tablets, a single dissolution 
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method for evaluating the in vitro release of Artemether and Lumefantrine 
from tablets was developed and validated. The method comprised of a 
dissolution medium of 1000 ml of2 %w/v of Myrj 52 in 0.005M HCl per 
vessel with the paddle rotating at 100 rpm for 120 min. The dissolution 
samples were analysed using a Waters HPLC system with Waters symmetry 
column (C-18column of 250mm x 4.6mm i.d., 5 µ particle size). The mobile 
phase was a mixture of 20 volumes of 0.5%v/v of tri ethylamine in water 
(adjusted to a pH of 3.0 with ortho phosphoric acid) and 80 volumes of 
Acetonitrile. The detection wavelength was set at 216 nm and 100 µl of each 
sample was injected. The HPLC method used for the determination of drug 
release was validated for the parameters of accuracy, precision, linearity, 
specificity, filter validation, solution stability and robustness. 
 
15. Isabella da Costa César et al27  had done Robustness evaluation of the 
chromatographic method for the quantitation of Lumefantrine using Youden’s 
test, it is a reliable method to evaluate the robustness of analytical methods, by 
means of an experiment design which involves seven analytical parameters 
combined in eight tests. In the present study, we assessed the robustness of a 
chromatographic method to quantify Lumefantrine in raw material samples, 
using Youden’s test. Hence, it was possible to determine the effect of each 
analytical parameter in the final analysis results. Youden’s test showed to be a 
simple and feasible procedure to evaluate the robustness of chromatographic 
methods. 
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16. MannurVinodh et al28 had done Analytical Method Development And 
Validation For Simultaneous Estimation Of Artemether And Lumefantrine In 
Pure And Pharmaceutical Dosage Form Using RP-HPLC Method, A simple, 
rapid, precise and cost effective reversed phase-high performance liquid 
chromatography (RP-HPLC) method was developed for the simultaneous 
estimation of Artemether (AT) and Lumefantrine (LU) in pure drug and 
pharmaceutical dosage forms. The separation was carried out using BDS 
Hypersil C18 (150 × 4.6 mm i.d. 3 µm particle size) column, with mobile 
phase comprising of 0.01M tetra butyl ammonium hydrogen sulphate and 
acetonitrile in the ratio of 20 : 80 (v/v). The flow rate was 1.0ml/min and the 
detection was carried out using UV-visible detector at 222 nm. The method 
was validated by evaluation of different parameters such as accuracy, 
precision, linearity, ruggedness, and robustness, limit of detection (LOD) and 
limit of quantification (LOQ). The retention time were found to be 4.19 and 
5.22 min for AT and LU, respectively. Correlation coefficient (r2) of 0.999 for 
both over concentration range of 3.2-19.2µg/ml and 16-96µg/ml for AT and 
LU, respectively. Parameters like mobile phase ratio, wavelength, flow rate, 
etc. were deliberately varied. It was observed that there were no marked 
changes in chromatograms, which demonstrated that the developed RP-HPLC 
method is robust. Intra and inter day precision reproducibility study was 
carried out and it was checked by determining precision on the same 
instrument, but by a different analyst. The percentage recovery for AT and LU 
were ranged between 99.18-100.19 and 99.96-100.07, respectively. The LOD 
for AT and LU were found to be 0.201 and 2.99 µg/ml and the LOQ were 
0.609 and 9.086 µg/ml respectively. Method was found to be reproducible 
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with relative standard deviation (RSD) for intra and inter day precision less 
than 2%. 
 
17. Mathieu Verbeken et al29 Stability-indicating HPLC-DAD/UV-ESI/MS 
impurity profiling of the anti-malarial drug Lumefantrine, it is a fluorine 
derivative belonging to the aryl amino alcohol class of anti-malarial drugs and 
is commercially available in fixed combination products with β-Artemether. 
Impurity characterization of such drugs, which are widely consumed in 
tropical countries for malaria control programes, is of paramount importance. 
However, until now, no exhaustive impurity profile of Lumefantrine has been 
established, encompassing process-related and degradation impurities in active 
pharmaceutical ingredients (APIs) and finished pharmaceutical products 
(FPPs). 
 
18. Karen Gaudin et al30 had done Simultaneous Determination of Artemether 
and Azithromycin in Suppositories by Reversed Phase HPLC, 
Chromatographic parameter assessments for RP-HPLC-UV method 
development for the simultaneous analysis of Artemether and Azithromycin 
for the pharmaceutical analysis of a rectal co formulation currently under 
development for the treatment of malaria infected children. Using methanol 
based mobile phase for the analysis of both Artemether and Azithromycin 
provided a more robust method in terms of resolution and peak symmetry. The 
method validated for suppository used 80% methanol and 20% phosphate 
buffer 15 mM at pH 9. The UV detection was at 210 nm. The accuracy 
profiles indicated a method validation between 80–120% for both active 
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pharmaceutical ingredients. The preparation process of the suppository was 
validated based on theoretical values of Artemether and Azithromycin present 
in the formulation; active pharmaceutical ingredients were homogenously 
distributed within the suppository. 
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3. AIM AND PLAN OF WORK 
   The aim of the work is to develop a new method for the analysis of 
Artemether and Lumefantrine by RP–HPLC in powder for oral suspension dosage 
form (dry syrup) and to validate it as per ICH guidelines. 
 Pharmaceutical industries rely upon quantitative chemical analysis to ensure 
that the raw materials used and the final product obtained meets their appropriate 
specification. The number of drugs and drug formulations introduced into the market 
has been increased and that product has been analyzed as per validated method. These 
drugs or formulations may be either new entities in the market or partial structural 
modification of the existing drugs or novel dosage forms or multi component dosage 
forms. 
  The multi component dosage forms proved to be effective due to combined 
mode of action on the body. The complicity of including the presence of multiple 
drug entities posses considerable challenge to the analytical chemist during the 
development of assay procedure. The estimation of individual drugs in these multi 
component dosage forms becomes difficult due to some extraction or isolation 
procedures. 
             For the present study Artemether and Lumefantrine was selected. The 
extensive literature survey carried out revealed that there is no method reported for 
the simultaneous estimation of these drugs in powder for oral suspension, some 
methods for estimation of combined drugs by HPLC and spectrophotometer are 
available. Hence present study aim to developing a specific, precise, accuracy, linear, 
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simple, rapid, and validated and cost effective RP-HPLC method for the simultaneous 
estimation of these drugs in combined dosage forms. 
The core of project for RP-HPLC method was designed as follows: 
1. Selection of suitable wavelength, 
2. Selection of mobile phase, 
3. Selection of initial separation conditions, 
4. Optimization of chromatographic conditions, 
5. Estimation of Artemether and Lumefantrine  
6. Method validation 
 Specificity 
 Linearity and Range 
 Precision 
 Accuracy 
 Ruggedness 
 Limit of detection 
 Limit of quantitation 
 Robustness   
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4. DRUG PROFILE 
ARTEMETHER 
Structure   :    
 
         
Molecular Formula  :  C16H26O5 
IUPAC name                         : (3R,5aS,6R,8aS,9R,10S,12R,12aR)-10-methoxy-3,6,9-
trimethyldecahydro-12H-3,12-epoxy[1,2] dioxepino 
[4,3-i]-2-benzopyran. 
Molecular weight : 298.374 g/mol 
Description : White crystalline powder.. 
Solubility                               : Insoluble in Water 
pKa(Strongest basic)           : 3.9  
Category             : Anti malarial. 
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Pharamacokinetic data: 
 Absorption: Absorption of Artemether is improved 2- to 3-fold with food. It is 
highly bound to protein (95.4%). Peak concentrations of Artemether are seen 2 
hours after administration 
 Metabolism: Artemether is metabolized in the human body to the active 
metabolite, dihydroartemisinin, primarily by hepatic enzymes CYP3A4/5.Both 
the parent drug and active metabolite are eliminated with a half-life of about 2 
hours 
 Elimination: Artemether cleared from plasma with an elimination half-life of 
about 2 hours.ntrine.  
Mechanism of action: 
Antimalarial agent Artemether is rapidly metabolized into an active metabolite 
dihydroartemisinin (DHA). The antimalarial activity of Artemether and DHA has 
been attributed to endoperoxide moiety.  
Toxicity: 
Impairment of Fertility: Pregnancy rates were reduced by about one-half in female 
rats dosed for 2 to 4 weeks with the Artemether Lumefantrine combination at 1000 
mg/kg (about 9 times the clinical dose based on body surface area comparisons). Male 
rats dosed for 70 days showed increases in abnormal sperm (87% abnormal) and 
increased testes weights at 30 mg/kg doses (about one-third the clinical dose). Higher 
doses (about 9 times the clinical dose) resulted in decreased sperm motility and 100% 
abnormal sperm cells. 
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Uses: 
 Artemether is an antimalarial drug for uncomplicated malaria caused by  P. 
falciparum (and chloroquine-resistant P. falciparum) or chloroquine-
resistant P. vivax parasites. Artemether can also be used to treat severe 
malaria.  
 The World Health Organization recommends the treatment of 
uncomplicated P. falciparum with artemisinin-based combination 
therapy.[11] Given in combination with lumefantrine, it may be followed by 
a 14 day regimen of primaquine to prevent relapse of P. vivax or P. 
ovale malarial parasites and provide a complete cure.  
 Artemether can also be used in treating and preventing trematode infections 
of schistosomiasis when used in combination with praziquantel.  
Storage: 
Store in a cool, dry place. Store in a tightly closed container. Recommended storage 
temperature: -20°C 
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 LUMEFANTRINE 
Structure                     
 
 
 
 
 
 
 
Molecular Formula : C30H32Cl3NO 
IUPAC Name        : 2-(Dibutylamino)-1-[(9Z)-2,7-dichloro-9-(4-chlorobenzylidene)-         
9H-fluoren-4-yl]ethanaol. 
Molecular weight     : 528.939 g/mol 
Description               : Pale pink colored amorphous solid 
Solubility                  : Soluble in Dimethyl sulfoxide  
pKa (strongest acidic) :     14.1 
pKa (strongest basic) :      9.78 
Category                      :Anti malarial 
Mechanism of action: 
Lumefantrine is a blood schizonticide active against erythrocytic stages 
of Plasmodium falciparum. It is thought that administration 
of Lumefantrine with Artemether results in cooperate antimalarial clearing 
effects. Artemether has a rapid onset of action and is rapidly cleared from the body. It 
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is thus thought to provide rapid symptomatic relief by reducing the number of 
malarial parasites. Lumefantrine has a much longer half life and is believed to clear 
residual parasites. 
Pharamacokineticdata : 
Absorption: Absorption of lumefantrine, a highly lipophilic compound, starts after 
a lag-time of up to 2 hours, with peak plasma concentrations about 6 to 
8 hours after administration. 
Metabolism: Lumefantrine was metabolized mainly by CYP3A4 to desbutyl 
Lumefantrine. The systemic exposure to the metabolite desbutyl-
Lumefantrine was less than 1% of the exposure to the parent 
compound. 
Elimination:   Lumefantrine is eliminated more slowly, with an elimination half-life 
of 3 to 6 days.  
Uses:  It is used to treatmalaria caused by Plasmodium falciparum 
Storage: Store in well-closed light-resistant containers at -20 0C 
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5.  MATERIALS AND INSTRUMENT USED 
 
5.1 CHEMICAL AND SOLVENTS USED: 
Table 5.1 
S. No. Name Grade Make Lot Number Purity 
01 
1-Hexane sulphonic 
acid sodium salt 
anhydrous  
HPLC Finar 96170713a15 99.00% 
02 
Monobasic sodium 
phosphate anhydrous AR Himedia 0000194436 98.00% 
03 Acetonitrile HPLC Finar 1285161012A0 99.80% 
04 Orthophosphoric acid AR Rankem G125D15 88.00% 
05 Ethanol AR 
Jiangsu 
Huaxi 
International  
20141205 99.90% 
06 HPLC  water AN water 
 
5.2 COLUMN USED: 
Table 5.2 
S.No. Make Column Name ID Serial No. 
01 Agilent ZorZorbax SB-C8, 5µm, 250mm x 4.6mm   
AD/LC 
CN/057 
USSH016106 
 
5.3 SAMPLE USED: 
Table 5.3 
Product name Batch number Mfg. Date Exp. Date 
Artemether and Lumefantrine  
for oral suspension(180 mg & 
1080 mg) 
FDPS590315 Mar-2015 NA 
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5.4 WORKING STANDARD, PLACEBO USED: 
Table 5.4 
.No. Name WS code Purity 
01 Artemether Working Standard CP2WS/080/00 99.41% 
02 Lumefantrine Working Standard CP2WS/078/00 99.47% 
03 Placebo Not Applicable 
 
5.5    INSTRUMENTS USED: 
Table 5.5 
S.No. Name Make & Model ID 
01 
Analytical Weighing 
Balance 
Mettler Toledo XS105 AD/INS/001 
02 HPLC  
Agilent 1260 & 1290 
series 
AD/INS/030 
03 pH Meter Hanna AD/INS/035 
04 Sonicator PCI India AD/INS/016 
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6. METHOD DEVELOPMENT AND VALIDATION 
Solubility 
Artemether is soluble in organic solvents such as ethanol, DMSO, and 
dimethyl formamide, which should be purged with an inert gas. The solubility of 
Artemether in these solvents is approximately 10 and 20 mg/ml, respectively. 
Artemether is sparingly soluble in aqueous buffers.  According to literature review 
Lumefantrine   very slightly soluble in acetonitrile and soluble in chloroform and 
dichloromethane, and it is practically insoluble (0.002%) in water. Finally buffer 
pH2.3, Ethanol and Acetonitrile in the ratio of 100:100:300 was selected as a solvent. 
Selection of Mobile Phase 
The pure drugs Artemether and Lumefantrine were injected in combination in 
the ratio of their contents in the formulation to the chromatographic system, and run 
in different mobile phase compositions. Different mobile phases containing different 
compositions of methanol: water, acetonitrile: water, acetonitrile: Phosphate buffer 
6.8 and acetonitrile: Phosphate buffer pH 2.3 was tried for the selection of optimum 
conditions for the simultaneous determination of Artemether and Lumefantrine. It was 
found that optimal separation of the two components was achieved with acetonitrile 
and phosphate buffer, compared to other mobile phases. Different ratios of the 
selected mobile phase were tried with varying flow rates and pH. Finally, the mobile 
phase composition selected for the chromatographic separation of Artemether and 
Lumefantrine was acetonitrile and phosphate buffer of pH 2.3 in the ration of 45:55 
v/v. 
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Selection of Analytical Wavelength 
UV Spectrophotometric determination of Artemether and Lumefantrine 
individually, shows that both the drugs absorb appreciably at 210nm, hence 210nm 
was selected as the detection wavelength. 
Figure: 6.1 UV Spectra of Artemether and Lumefantrine 
 
Optimized Chromatographic Conditions 
Chromatographic conditions: 
Column             : C8, 15 cm x 4.6-mm, 5-µm [Zorbax SB-C8 is suitable] 
Flow Rate                : 2.0 mL/minute 
Pump mode   : Isocratic 
Detector Wavelength              : 210 nm  
Injection volume             : 20 µL 
Column Temperature       : 40°C 
Lumefantrine 
Artemether 
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Sample Temperature       : 20°C 
Mobile phase : Prepared a mixture 450 volume of buffer (pH:2.3) and        
550 volume of Acetonitrile, mixed. Filtered the solution 
through 0.45 µm nylon filter and sonication was done 
for 10 minutes. 
Methodology adopted 
 Preparation of buffer solution 
 Preparation of mobile phase 
 Preparation of diluent 
 Preparation of standard stock solution 
 Preparation of standard solution 
 Preparation of sample solution 
 Preparation of Placebo solution 
 Setting the instrumental parameters before performing the analysis 
for Detector and Pump 
 Development of chromatogram and determination of retention time. 
Preparation of buffer (pH 2.3): 
Weighed and dissolved 5.65 g of 1-Hexane sulphonic acid sodium salt anhydrous and 
2.75 gm of sodium phosphate monobasic anhydrous in 1000 mL of purified water, 
mixed well. Adjusted  the  pH to 2.3 with dilute phosphoric acid. 
Preparation of dilute Orthophosphoric acid: 
Transferred 6.9 mL of orthophosphoric acid through pipette into 100 mL volumetric 
flask and diluted up to the volume with water. 
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Preparation of Mobile phase: 
Prepared a mixture 450 volume of buffer and 550 volume of Acetonitrile, mixed. 
Filtered the solution through 0.45 µm nylon filter and sonication was done for 10 
minutes. 
Preparation of Diluent: 
Prepared a mixture of buffer, Ethanol and Acetonitrile in the ratio of 100:100:300. 
Filtered the solution through 0.45 µm nylon filter and sonication was done for 10 
minutes and mixed. 
Procedure for preparation of analytical solutions 
Preparation of standard solution 320.0 mcg/mL of Artemether and 120.0 
mcg/mL of Lumefantrine 
Weighed accurately 80 mg of Artemether working standard, 30 mg of Lumefantrine 
working standard and transferred into 250 mL volumetric flask, added 100 mL of 
diluent and sonication was done for 15 minutes and dissolved, cooled and diluted up 
to the volume with diluent and mixed. Filtered the solution through 0.45 µm nylon 
filter and collected the solution in HPLC vial after discarded first 2 mL of the filtrate. 
Estimation of sample solution of Artemether 320.0 mcg/mL and Lumefantrine 
120.0 mcg/mL 
Constituted Artemether and Lumefantrine for Oral Suspension with water up to the 
volume specified in the labeling. Weighed accurately about 80 mg (about 29.46 g of 
sample) for Artemether and 30 mg (about 1.85 g of sample)  for  Lumefantrine 
transferred in to 250 mL volumetric flask respectively. Added 120 mL of diluent to 
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each and shaked by mechanical for 30 minutes and sonication was done for 20 
minutes with intermediate shaking and dissolved, cooled and diluted up to volume 
with diluent. Mixed and filtered the solution through 0.45 µm Nylon filter and 
collected the sample solution in HPLC vial after discarded first 2 mL of the filtrate. 
The chromatogram was showed in chromatogram no.7.7 and 7.8. 
Placebo solution for Artemether and Lumefantrine   
Weighed accurately 29.8267 g of placebo for Artemether and 1.8391 g of placebo for 
Lumefantrine (based on density 1.1215g/mL) and transferred into 250 mL volumetric flask 
respectively. Added 120 mL of diluent to each and shaked by mechanical for 30 minutes and 
sonication was done for 20 minutes with intermediate shaking and dissolved, cooled and 
diluted up to volume with diluent. Mixed and filtered the solution through 0.45 µm Nylon 
filter and collected the sample solution in HPLC vial after discarded first 2 mL of the filtrate. 
The chromatogram was showed in chromatogram no.7.5. 
CALCULATIONS 
Content of Artemether in mg: 
    SPL Area     STD wt in mg           250           STD Purity in ASB                  
= ----------- X------------------- X ------------- X -------------------- x Weight per mL x 60 
   STD Area            250               SPL wt in g               100    
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Content of Artemether in Percentage (%): 
                Artemether in mg 
= ---------------------------------------------------------------------- x 100 
            Label claim of Artemether in each 60 mL contains in mg. 
 
Content of Lumefantrine in mg: 
   SPL Area      STD wt in mg      250          STD Purity in ASB                  
= ----------- X----------------- X ----------- X -------------------x Weight per mL x 60 
    STD Area          250              SPL wt in g             100 
Content of Lumefantrine in Percentage (%): 
                                   Lumefantrine in mg 
= -------------------------------------------------------------------------- x 100 
          Label claim of Lumefantrine in each 60 mL contains in mg 
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 METHOD VALIDATION 
Validation of analytical method is a process to establish that the performance 
characteristics of the developed method meet the requirement of the intended 
analytical application. (Lloyd R. Synder, 1997)4 (ICH Harmonized Tripartite 
Guidelines, 2005)6 
SYSTEM SUITABILITY PARAMETERS 
System suitability is the test to ensure that the methods can generate results 
of acceptable accuracy and precision. (Lloyd R. Synder, 1997) 4 
Parameters studied  
Tailing Factor. 
Number of theoretical plates (N).  
Retention time. 
Relative standard deviation. 
Typical analytical parameters used in method validation include 
1.   Specificity 
2.   Linearity and Range 
3.   Precision 
4.   Accuracy 
5.   Ruggedness 
6.   Limit of detection 
7.   Limit of quantitation 
8.   Robustness 
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SPECIFICITY 
The  specificity of  the  method  can  be  defined  as  the  ability to  measure 
accurately the concentration of an analyte in the presence of all other sample 
materials. (Lloyd R. Synder, 1997)4 (ICH Harmonized Tripartite Guidelines, 2005)6 
Procedure: 
Inject the blank, placebo, standard and sample preparations based on “Injection 
sequence” detailed below and measure the corresponding area. 
Table No: 6.1 Injection sequence for Specificity 
Particulars Number of Injection 
Blank 1 
Placebo preparation 1 
Standard preparation 5 
Sample preparation 2 
Bracketing standard 1 
 
Acceptance criteria: 
No any peak should be obtained in the retention time of Artemether and 
Lumefantrine from the blank and placebo chromatograms. 
LINEARITY AND RANGE 
Linearity is  the  measure  of  how  well  a  calibration  plot  of  response  Vs 
concentration approximates a straight line. Linearity can be assessed by performing 
the single measurement s at several analyte concentrations. The data are then 
processed using a linear least square regression. The resulting plot slope, intercept and 
correlation coefficient provide the desired information on linearity.  
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  Ability to obtain test results which are directly proportional to the 
concentration of analyte. For an establishment of the linearity 60%, 80%, 100%, 
120%, and 160% of standard and sample concentrations shall be used. 
Preparation of Linearity from standard: 
Standard stock solution  
Weighed accurately 160 mg of Artemether working standard, 60mg of Lumefantrine 
working standard and transferred into 250 mL volumetric flask, added 100 mL of 
diluent and sonication was done for 15 minutes and dissolved, cooled and diluted up 
to the volume with diluent and mixed.  
60 % Linearity standard concentration (192.0 mcg/mL of Artemether and 72.0 
mcg/mL of Lumefantrine): 
Transfer 3.0 mL of above standard stock solution through pipette into a 10 mL 
volumetric flask and dilute up to the volume with diluent and mix. Filter the solution 
through 0.45 µm nylon membrane filter and collect the solution in an HPLC vial after 
discarding about the first 2 mL of the filtrate. 
80 % Linearity standard concentration (256.0 mcg/mL of Artemether and 96.0 
mcg/mL of Lumefantrine): 
Transfer 4.0 mL of above standard stock solution through pipette  into a 10 mL 
volumetric flask and dilute up to the volume with diluent and mix. Filter the solution 
through 0.45 µm nylon membrane filter and collect the solution in an HPLC vial after 
discarding about first 2 mL of filtrate. 
100 % Linearity standard concentration (320.0 mcg/mL of Artemether and 120.0 
mcg/mL of Lumefantrine): 
Transfer 5.00 mL of above standard stock solution through pipette  into a 10 mL 
volumetric flask and dilute up to the volume with mobile phase and mix. Filter the 
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solution through 0.45 µm nylon membrane filter and collect the solution in an HPLC 
vial after discarding about the first 2 mL of the filtrate. 
120 % Linearity standard concentration (384.0 mcg/mL of Artemether and 144.0 
mcg/mL of Lumefantrine): 
Transfer 6.0 mL of above standard stock solution through pipette  into a 10 mL 
volumetric flask and dilute up to the volume with diluent and mix. Filter the solution 
through 0.45 µm nylon membrane filter and collect the solution in an HPLC vial after 
discarding about the first 2 mL of the filtrate. 
160 % Linearity standard concentration (512.0 mcg/mL of Artemether and 192.0 
mcg/mL of Lumefantrine): 
Transfer 8 mL of above standard stock solution through pipette into a 10 mL 
volumetric flask and dilute up to the volume with diluent and mix. Filter the solution 
through 0.45 µm nylon membrane filter and collect the solution in an HPLC vial after 
discarding about the first 2 mL of the filtrate. 
Acceptance criteria: 
 Correlation co-efficient between concentrations and its area should be more than    
0.998. 
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PRECISION 
 Precision is the measure of the repeatability of result. The precision of an analytical 
procedure expresses the closeness of agreement between a series of measurements 
under the prescribed conditions. 
SYSTEM PRECISION 
Determines the closeness of agreement of the same homogenous standard 
preparations under the prescribe conditions.   
Procedure:   
Inject the blank, standard preparations based on “Injection sequence” detailed below 
and measure the corresponding area. 
Table No: 6.2 Injection sequence for System Precision 
Particulars Number of Injection 
Blank 1 
Standard preparation 6 
 
 Acceptance criteria 
 The Tailing factor of the peak due to Artemether and Lumefantrine obtained from five 
replicates standard solution injections should be not more than 3.0. 
 Theoretical plates of the peak obtained for five replicates standard solution injections 
of Artemether and Lumefantrine should be not less than 2000. 
 The relative standard deviation of the area obtained for Five replicate standard 
solution of Artemether and Lumefantrine should be not more than 2.0%. 
 The relative standard deviation of the retention time obtained for five replicate 
standard solution of Artemether and Lumefantrine should be not more than 1.0%. 
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METHOD PRECISION (REPEATABILITY) 
Determines the closeness of agreement of the same homogenous sample under the 
prescribe conditions. Performing assay of Artemether and Lumefantrine for Oral 
Suspension (180 mg & 1080 mg), a minimum of six sample preparation from a single 
batch shall be made and analyze separately. 
Procedure 
Inject the blank, standard and sample preparations based on “Injection sequence” 
detailed below and measure the corresponding area. 
Table No: 6.3 Injection sequence for Method Precision 
 
Acceptance criteria: 
 Assay obtained for each six sample preparations should be between 90.0 and 110% 
 The RSD obtained for the assay results for six sample preparations should be not   
more   than 2.0 %. 
 
 
 
 
    
Particulars Number of Injection 
Blank 1 
Standard Preparation 6 
Sample preparations for Artemether– 1, 2, 3, 4, 5 & 6 Each 2 
Sample preparations for Lumefantrine– 1, 2, 3, 4, 5 & 6 Each 2 
Bracketing Standard 1 
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ACCURACY  
Accuracy is defined as closeness of measured value to the true value. The accuracy of 
an analytical procedure expresses the closeness of agreement between the value which 
is accepted either as a conventional true value or an accepted reference value and the 
value found. 
Preparation of analytical solution 
Preparation of Standard solution (320.0 mcg/mL of Artemether and 120.0 
mcg/mL of Lumefantrine) 
Weigh accurately about 80.0 mg of Artemether working standard, 30 mg of 
Lumefantrine working standard, and transfer in to 250 mL volumetric flask, Add 100 
mL of diluent and sonicate for 15 minutes to dissolve. Cool and dilute up to the 
volume with diluent and mix well. Filter the solution through 0.45 µm Nylon filter 
and collect the sample solution in HPLC vial after discarding about first 2 mL of the 
filtrate. 
Accuracy Sample preparation for Artemether 
Placebo spiked with 50 % standard solution preparation (160.0 mcg/mL of 
Artemether) 
Accurately weigh 40 mg of Artemether WS, 29.8267g of Artemether and 
Lumefantrine for Oral Suspension (180 mg & 1080 mg) placebo (based on density 
1.1215g/mL) and transfer into 250 mL volumetric flask. Add about 100 mL of diluent 
and sonicate for 20 minutes with intermediate shaking to dissolve. Cool and dilute up 
to volume with diluent. Filter the solution through 0.45 µm Nylon filter and collect 
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the sample solution in HPLC vial after discarding about first 2 mL of the filtrate. 
Prepare the sample preparation in triplicate. 
Placebo spiked with 100 % standard solution preparation (320.0 mcg/mL of 
Artemether) 
Accurately weigh 80 mg of Artemether WS, 29.8267g of Artemether and 
Lumefantrine for Oral Suspension (180 mg & 1080 mg) placebo (based on density 
1.1215g/mL)  and transfer into 250 mL volumetric flask. Add about 100 mL of 
diluent and sonicate for 20 minutes with intermediate shaking to dissolve. Cool and 
dilute up to volume with diluent. Filter the solution through 0.45 µm Nylon filter and 
collect the sample solution in HPLC vial after discarding about first 2 mL of the 
filtrate. Prepare the sample preparation in triplicate. 
Placebo spiked with 150 % standard solution preparation (480.0 mcg/mL of 
Artemether) 
Accurately weigh 120 mg of Artemether WS, 29.8267g of Artemether and 
Lumefantrine for Oral Suspension (180 mg & 1080 mg) placebo (based on density 
1.1215g/mL) and transfer into 250 mL volumetric flask. Add about 100 mL of diluent 
and sonicate for 20 minutes with intermediate shaking to dissolve. Cool and dilute up 
to volume with diluent. Filter the solution through 0.45 µm Nylon filter and collect 
the sample solution in HPLC vial after discarding about first 2 mL of the filtrate. 
Prepare the sample preparation in triplicate. 
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Accuracy Sample preparation for Lumefantrine 
Placebo spiked with 50 % standard solution preparation (60.0 mcg/mL of 
Lumefantrine) 
Accurately weigh 15 mg of Lumefantrine WS, 1.8391g of Artemether and 
Lumefantrine for Oral Suspension (180 mg & 1080 mg) placebo (based on density 
1.1215g/mL) and transfer into 250 mL volumetric flask. Add about 100 mL of diluent 
and sonicate for 20 minutes with intermediate shaking to dissolve. Cool and dilute up 
to volume with diluent. Filter the solution through 0.45 µm Nylon filter and collect 
the sample solution in HPLC vial after discarding about first 2 mL of the filtrate. 
Prepare the sample preparation in triplicate.  
Placebo spiked with 100 % standard solution preparation (120.0 mcg/mL of 
Lumefantrine) 
Accurately weigh 30 mg of Lumefantrine WS, 1.8391g of Artemether and 
Lumefantrine for Oral Suspension (180 mg & 1080 mg) placebo (based on density 
1.1215g/mL) and transfer into 250 mL volumetric flask. Add about 100 mL of diluent 
and sonicate for 20 minutes with intermediate shaking to dissolve. Cool and dilute up 
to volume with diluent. Filter the solution through 0.45 µm Nylon filter and collect 
the sample solution in HPLC vial after discarding about first 2 mL of the filtrate. 
Prepare the sample preparation in triplicate. 
Placebo spiked with 150 % standard solution preparation (180.0 mcg/mL of 
Lumefantrine) 
Accurately weigh 45 mg of Lumefantrine WS, 1.8391g of Artemether and 
Lumefantrine for Oral Suspension (180 mg & 1080 mg) placebo (based on density 
1.1215g/mL) and transfer into 250 mL volumetric flask. Add about 100 mL of diluent 
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and sonicate for 20 minutes with intermediate shaking to dissolve. Cool and dilute up 
to volume with diluent. Filter the solution through 0.45 µm Nylon filter and collect 
the sample solution in HPLC vial after discarding about first 2 mL of the filtrate. 
Prepare the sample preparation in triplicate.  
Procedure 
Inject the blank, standard and placebo spiked standard preparations based on 
“Injection sequence” detailed below and measure the corresponding area. 
Table: 6.4 Injection sequence for Accuracy 
Particulars 
No. of  
injections 
Blank 1 
Standard preparation 6 
Placebo spiked with 50 % Artemether standard preparation 1, 2 & 3 Each 3 
Placebo spiked with 100 % Artemether standard preparation 1, 2 & 3 Each 3 
Placebo spiked with 150 % Artemether standard preparation 1, 2 & 3 Each 3 
Placebo spiked with 50 % Lumefantrine standard preparation 1, 2 & 3 Each 3 
Placebo spiked with 100 % Lumefantrine standard preparation 1, 2 & 3 Each 3 
Placebo spiked with 150 % Lumefantrine standard preparation 1, 2 & 3 Each 3 
Bracketing Standard 1 
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Calculations for Artemether accuracy: 
Step 1: Standard added in mg (Working standard solution) 
      Standard wt in mg         
=  --------------------------- 
               250     
Step 2: Placebo spiked standard added in mg at 100% 
      Wt. of spiked standard in mg             
=  -------------------------------------  
                     250                              
Step 3: Placebo spiked standard recovered in mg 
          Placebo spiked standard area X standard added in mg (Working standard 
solution) 
=  ------------------------------------------------------------------------------------------------ 
                              Average area of working standard solution 
Step 4: Recovery in percentage 
     Placebo spiked standard recovered in mg 
=   ------------------------------------------------- X 100 
        Placebo spiked standard added in mg 
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Calculations for Lumefantrine accuracy 
Step 1: Standard added in mg (Working standard solution) 
      Standard wt in mg            
=  -------------------------- 
              250          
Step 2: Placebo spiked standard added in mg at 100% 
       Wt. of spiked standard in mg     
=    ------------------------------------- 
                       250                              
Step 3: Placebo spiked standard recovered in mg 
         Placebo spiked standard area X standard added in mg (Working standard 
solution)       
= ------------------------------------------------------------------------------------------------ 
                              Average area of working standard solution                                  
Step 4: Recovery in percentage 
     Placebo spiked standard recovered in mg 
=  ----------------------------------------------------- X 100 
     Placebo spiked standard added in mg 
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Acceptance criteria 
In each concentration, the ranitidine hcl working standard spiked with placebo 
should be recovered between 98.0 % and 102.0 %. 
 
RUGGEDNESS  
Defined by USP, The Ruggedness is the degree of reproducibility of test results  
obtained  under  a  variety  of  conditions,  such  as  different  laboratories, analysts,  
instruments,  environmental  conditions,  operators  and  materials. Ruggedness is a 
measure of reproducibility of test results under normal, expected operational 
conditions from laboratory and from analyst to analyst. 
Procedure 
Working standard solutions and working sample solution were prepared by different 
analyst on different days. Solutions were injected as per the test method and 
chromatograms were recorded. 
Inject the blank, standard and sample solution preparations based on “Injection 
sequence” detailed below and measure the corresponding area. 
Table No: 6.5 Injection sequence for Ruggedness 
 
 
Particulars Number of Injection 
Blank 1 
Standard preparation 5 
Sample preparations – 1, 2, 3   (Analyst 1 and 2) Each 2 
Bracketing   Standard 1 
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Acceptance criteria: 
 Assay in % obtained for each six sample preparations should be between 90.0 and 110 
% 
 The RSD obtained for the assay results for six sample preparations should be not 
more than 2.0 %. 
  
ROBUSTNESS  
Robustness of an analytical method is measure of its capacity to remain unaffected 
by small but deliberate variation in method parameters. It provides information about 
the reliability of method. 
Determination 
The robustness of an analytical method is determined by analysis of aliquots of 
homogenous lots by differing physical parameters like flow rate and column 
temperature. 
Change in flow rate plus (2.2 mL/minute): 
For Chromatographic conditions, follow the method of analysis  except by changing 
the flow to 2.2 mL / minute instead of 2.0 mL / minute. 
 Change in flow rate minus (1.8 mL/minute): 
For Chromatographic conditions, follow the method of analysis except by changing 
the flow to 1.8 mL / minute instead of 2.0 mL / minute. 
Change in wavelength plus (212 nm): 
For Chromatographic conditions, follow the method of analysis except   by changing 
the wavelength to 212 nm instead of 210 nm. 
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 Change in wavelength minus (208nm): 
For Chromatographic conditions, follow the method of analysis except    by changing 
the wavelength to 208nm instead of 210 nm. 
Change in mobile phase organic content plus (+5%): 
  Change the least organic solvents ratio to 57.5 volumes instead of 55 volume, and 
adjust the quantity variation from Buffer concentration to maintain 100 %.  
 Change in mobile phase organic content minus (-5%): 
 Change the least organic solvents ratio to 52.25 volumes instead of 55 volumes, and 
adjust the quantity variation from Buffer concentration to maintain 100%.  
Inject the blank, standard and sample solution preparations based on “Injection 
sequence” detailed below and measure the corresponding area. 
Table No: 6.6 Injection sequence for Robustness 
 
Acceptance criteria: 
   Assay obtained for each robustness parameter should be between 90.0 and 
110.0%.The combined RSD obtained for the assay result of an each robustness 
parameter and six assay results of method precision should be not more than 2.0 %.    
STABILITY STUDIES  
Stability of the sample and standard  solutions used  in  HPLC  method  is required  
to  generate reproducible and  reliable results. The sample and  standard solutions  
Particulars Number of Injection 
Blank 1 
Standard solution  5 
Sample solution  2 
Bracketing standard solution 1 
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were  subjected  to  short  term  stability  studies  at  room  temperature. Stability 
studies were carried out initially, at 8 hours and 16 hours, 24 hours time lapse of 
solution preparation. This study should be performed by injecting standard solution 
and sample solution at probable time points, and minimum not less than 24 hours 
shall be studied. 
Note:  
Maintain the chromatographic conditions and solutions preparation as per the 
procedure given in method of analysis and injections sequence for solution stability 
study is given in below table. 
The maximum time for inject able usage of standard and sample solution is absolutely 
depends on the 24 Hours of solutions stability studied. 
Injection sequence:  
Table No: 6.7 Injection sequence for Solution Stability 
Particulars Number of Injections 
Blank  (0 Hour) 1 
Standard preparation (0 Hour) 1 
Sample preparation  (0 Hour) 1 
Blank  (X Hours) 1 
Standard preparation (X Hours) 1 
Sample preparation  (X Hours) 1 
 
Acceptance criteria: 
Cumulative % RSD for area obtained between initial time point and various probable 
intervals time points should be not more than 2.0 %. 
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7. CHROMATOGRAMS 
 
Method Development 
 
 
Chromatogram No – 7.1 
Trail No.1 
 
 
 
 
 
Chromatogram No – 7.2 
Trail No.2 
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Chromatogram No – 7.3 
Trail No.3 
 
 
 
 
 
Method Validation 
 
SPECIFICITY   
(Blank, Standard & Sample) 
 
Chromatogram No – 7.4 
 
Blank 
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Chromatogram No 7.5 
 
Placebo 
 
 
 
 
 
 
Chromatogram No – 7.6 
 
 
Standard 
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Chromatogram No – 7.7 
 
Arthemether  Sample Preparation 
 
 
 
 
 
Chromatogram No – 7.8 
 
Lumefantrine  Sample Preparation 
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LINEARITY AND RANGE  
  
(Blank, Standards, linearity samples 60% ,80%,100%,120%,160%)   
 
Chromatogram No – 7.9 
  
Blank 
 
 
Chromatogram No – 7.10  
Standard 
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Chromatogram No – 7.11  
Linearity 60%  
 
 
 
 
 
Chromatogram No – 7.12 
 
Linearity 80% 
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Chromatogram No – 7.13  
Linearity 100%  
 
 
 
 
Chromatogram No – 7.14  
Linearity 120%  
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Chromatogram No – 7.15  
Linearity 160%  
 
 
 
 
 
PRECISION-SYSTEM PRECISION  
 
(Blank and standards) 
Chromatogram No – 7.16  
Blank 
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Chromatogram No – 7.17  
System precision  
 
 
PRECISION-METHOD PRECISION  
 
(Blank, standards, Sample preparations) 
 
Chromatogram No – 7.18 
 
Blank 
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Chromatogram No – 7.19 
 
Standard  
 
 
 
 
 
Chromatogram No – 7.20  
Artemether Sample Preparation - 01 
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Chromatogram No – 7.21 
 
Artemether sample preparation – 02 
 
 
 
  
 
                    
 
Chromatogram No – 7.22 
 
Artemether sample preparation -03 
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Chromatogram No – 7.23 
 
Artemether sample preparation -04 
 
 
 
 
 
 
 
  
Chromatogram No – 7.24 
  
Artemether sample preparation -05 
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Chromatogram No – 7.25 
 
Artemether sample preparation - 06 
 
 
 
 
 
 
 
 
Chromatogram No – 7.26  
Lumefantrine Sample Preparation - 01 
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Chromatogram No – 7.27  
Lumefantrine Sample Preparation - 02 
 
 
 
 
 
 
 
 
Chromatogram No – 7.28 
  
Lumefantrine Sample Preparation - 03 
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Chromatogram No – 7.29 
 
Lumefantrine Sample Preparation - 04  
 
 
 
 
 
 
Chromatogram No – 7.30 
 
Lumefantrine Sample Preparation - 05  
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Chromatogram No – 7.31 
 
Lumefantrine Sample Preparation - 06 
 
 
 
 
 
 
  
ACCURACY 
Chromatogram No – 7.32   
Blank 
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Chromatogram No – 7.33  
Standard 
 
 
 
 
 
 
 
Chromatogram No – 7.34  
Accuracy 50%- Artemether Preparation-1 
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Chromatogram No – 7.35  
Accuracy 50% - Artemether Preparation-2  
 
 
 
 
 
 
Chromatogram No – 7.36  
Accuracy 50% - Artemether Preparation-3 
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Chromatogram No – 7.37 
 
Accuracy 100% - Artemether Preparation-1 
 
 
 
 
 
 
 
 
Chromatogram No – 7.38  
Accuracy 100% -Artemether Preparation-2 
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Chromatogram No – 7.39  
Accuracy 100% - Artemether Preparation-3 
 
 
 
 
 
 
 
 
Chromatogram No – 7.40  
Accuracy 150% - Artemether Preparation-1 
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Chromatogram No – 7.41  
Accuracy 150% - Artemether Preparation-2 
 
 
 
 
 
 
 
 
 
Chromatogram No – 7.42 
 
Accuracy 150% - Artemether Preparation-3 
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Chromatogram No – 7.43  
Accuracy 50 %- Lumefantrine Preparation-1 
 
 
 
 
 
 
Chromatogram No – 7.44 
 
Accuracy 50% - Lumefantrine Preparation-2 
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Chromatogram No – 7.45 
 
Accuracy 50% - Lumefantrine Preparation-3  
 
 
 
 
 
 
Chromatogram No – 7.46  
Accuracy 100% - Lumefantrine Preparation-1  
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Chromatogram No – 7.47 
 
Accuracy 100% - Lumefantrine Preparation-2  
 
 
 
 
 
 
 
Chromatogram No – 7.48 
 
Accuracy 100% - Lumefantrine Preparation-3  
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Chromatogram No – 7.49 
 
Accuracy 150 % - Lumefantrine Preparation-1 
 
 
 
 
 
 
 
 
Chromatogram No – 7.50  
Accuracy 150% - Lumefantrine Preparation-2  
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Chromatogram No – 7.51 
 
Accuracy 150% - Lumefantrine Preparation-3 
 
 
 
RUGGEDNESS (INTERMEDIATE PRECISION) 
 
(Blank ,standards, Sample preparations)   
Chromatogram No – 7.52 
 
Blank 
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Chromatogram No – 7.53  
Standard  
 
 
 
 
 
 
Chromatogram No – 7.54 
Artemether Sample Preparation – 1 
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Chromatogram No – 7.55  
Artemether Sample Preparation - 2 
 
 
 
 
 
 
 
Chromatogram No – 7.56 
 
Artemether Sample Preparation - 3 
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Chromatogram No – 7.57 
 
Artemether Sample Preparation - 4  
 
 
 
 
 
 
 
Chromatogram No – 7.58  
Artemether Sample Preparation - 5   
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Chromatogram No – 7.59 
 
Artemether Sample Preparation – 6 
 
  
 
 
 
 
 
Chromatogram No – 7.60 
 
Lumefantrine Sample Preparation - 1 
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Chromatogram No – 7.61  
Lumefantrine Sample Preparation - 2 
  
 
 
 
 
 
Chromatogram No – 7.62  
      Lumefantrine Sample Preparation - 3 
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Chromatogram No – 7.63 
 
Lumefantrine Sample Preparation - 4   
 
 
 
 
 
Chromatogram No – 7.64  
Lumefantrine Sample Preparartion - 5   
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Chromatogram No – 7.65 
 
Lumefantrine Sample Preparation - 6  
 
 
 
 
 
 
ROBUSTNESS 
Chromatogram No – 7.66  
Change in the wave length -208 nm - Blank 
  
 
 
 
 
 
 
 
 
 
 
 
Chapter – 7                                                                                                   Chromatograms 
 
Dept. of Pharmaceutial Analysis              114               J.K.K.Nattraja College of Pharmacy 
Chromatogram No – 7.67 
 
Change in the wave length -208 nm - Standard 
 
 
 
 
 
 
 
Chromatogram No – 7.68 
 
Change in the wave length - 208 nm – Sample Artemether 
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Chromatogram No – 7.69 
 
Change in the wave length - 208 nm – Sample Lumefantrine  
 
 
 
 
 
 
Chromatogram No – 7.70 
 
Change in the wave length - 212 nm - Blank  
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Chromatogram No – 7.71  
Change in the wave length – 212 nm – Standard 
  
 
 
 
 
 
 
Chromatogram No – 7.72  
Change in the wave length – 212 nm – Sample Artemether 
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Chromatogram No – 7.73 
 
Change in the wave length -212 nm –Sample Lumefantrine  
 
 
 
 
 
 
Chromatogram No – 7.74 
 
Change in the flow rate - 2.2 ml - Blank   
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Chromatogram No – 7.75 
 
Change in the flow rate -2.2ml  - Standard 
 
 
 
 
 
 
 
Chromatogram No – 7.76 
 
Change in the flow rate -2.2ml - Sample Artemether  
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Chromatogram No – 7.77 
 
Change in the flow rate -2.2ml - Sample Lumefantrine 
 
 
 
 
 
Chromatogram No – 7.78  
Change in the flow rate -1.8 ml – Blank 
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Chromatogram No – 7.79 
 
Change in the flow rate -1.8 ml - Standard 
 
 
 
Chromatogram No – 7.80 
 
Change in the flow rate -1.8 ml - Sample Artemether  
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Chromatogram No – 7.81 
 
Change in the flow rate -1.8 ml  - Sample Lumefantrine  
  
  
 
Chromatogram No – 7.82 
 
Change in mobile phase organic content plus 5% - Blank  
  
 
 
 
 
 
Chapter – 7                                                                                                   Chromatograms 
 
Dept. of Pharmaceutial Analysis              122               J.K.K.Nattraja College of Pharmacy 
Chromatogram No – 7.83 
 
Change in mobile phase organic content plus 5% - Standard 
      
Chromatogram No – 7.84  
Change in mobile phase organic content plus 5% - Sample Artemether  
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Chromatogram No – 7.85  
Change in mobile phase organic content plus 5% - Sample Lumefantrine 
 
 
 
 
Chromatogram No – 7.86 
 
Change in mobile phase organic content minus 5% - Blank 
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Chromatogram No – 7.87 
 
Change in mobile phase organic content minus 5% - Standard 
 
 
 
 
Chromatogram No – 7.88 
 
Change in mobile phase organic content minus 5% - Sample Artemether  
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Chromatogram No – 7.89 
 
Change in mobile phase organic content minus 5% - Sample Lumefantrine 
   
 
 
 
STABILITY OF ANALYTICAL SOLUTIONS  
(Standard, Sample) 
 
Chromatogram No – 7.90  
0 hour – Standard 
  
 
 
 
 
 
 
 
Chapter – 7                                                                                                   Chromatograms 
 
Dept. of Pharmaceutial Analysis              126               J.K.K.Nattraja College of Pharmacy 
Chromatogram No – 7.91 
 
0 hour – Sample Artemether 
 
 
 
 
Chromatogram No – 7.92 
 
0 hour – Sample Lumefantrine 
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Chromatogram No – 7.93 
 
3rd hour – Standard 
 
 
 
 
Chromatogram No – 7.94  
3rd hour – Sample Artemether 
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Chromatogram No – 7.95  
3rd hour – Sample Lumefantrine 
 
  
 
 
Chromatogram No – 7.96 
 
6th hour – Standard 
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Chromatogram No – 7.97 
 
6th hour – Sample Artemether 
 
 
 
 
 
 
Chromatogram No – 7.98  
6th hour – Sample Lumefantrine 
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Chromatogram No – 7.99 
 
9th hour –Standard 
 
 
 
 
Chromatogram No – 7.100 
 
9th hour – Sample Artemether 
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Chromatogram No – 7.101 
 
9th hour – Sample Lumefantrine 
 
     
 
Chromatogram No – 7.102  
12th   hour – Standard 
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Chromatogram No – 7.103 
 
12th   hour – Sample Artemether 
 
 
 
 
 
Chromatogram No – 7.104 
 
12th   hour – Sample Lumefantrine 
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Chromatogram No – 7.105 
 
15th   hour – Standard 
 
    
 
Chromatogram No – 7.106 
 
15th   hour – Sample Artemether 
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Chromatogram No – 7.107 
 
15th   hour – Sample Lumefantrine 
 
 
 
 
Chromatogram No – 7.108 
 
18th   hour – Standard 
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Chromatogram No – 7.109 
 
18th   hour – Sample Artemether 
 
 
 
 
Chromatogram No – 7.110 
 
18th   hour – Sample Lumefantrine 
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Chromatogram No – 7.111 
 
21st   hour – Standard 
 
 
 
 
Chromatogram No – 7.112 
 
21st   hour –Sample Artemether 
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Chromatogram No – 7.113 
 
21st   hour –Sample Lumefantrine 
 
  
 
Chromatogram No – 7.114 
 
24th   hour – Standard 
 
     
 
 
 
 
 
 
 
Chapter – 7                                                                                                   Chromatograms 
 
Dept. of Pharmaceutial Analysis              138               J.K.K.Nattraja College of Pharmacy 
Chromatogram No – 7.115 
 
24th   hour – Sample Artemether 
 
 
 
 
Chromatogram No – 7.116 
 
24th   hour – Sample Lumefantrine 
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8. RESULT AND DISCUSSION 
A simple Reverse phase high performance liquid chromatographic method has been 
developed and subsequently validated for Artemether and Lumefantrine powder for 
oral suspension dosage form (dry syrup). 
 The separation was carried out by using mobile phase composition 
selected for the chromatographic separation of Artemether and Lumefantrine was 
acetonitrile and phosphate buffer of pH 2.3 in the ration of 45:55 v/v. The detection 
was carried out at 210 nm. The column was Zorbax SB C8 (150 x 4.6mm, 5µ). The 
flow rate was selected as 2mL/min. 
SPECIFICITY 
Table No: 8.1 Specificity System Suitability Report 
S.No. Parameter 
Results obtained Acceptance 
criteria Artemether Lumefantrine 
01 
Tailing factor from five 
replicate injections 
1.03 2.32 NMT 3.0 
02 
Theoretical Plates from 
five replicate injections 
9396 3843 NLT 2000 
03 
% RSD of area for five 
standard injections 
0.100 0.089 NMT 2.0 % 
04 
Resolution between 
Artemether and 
Lumefantrine 
17 
 
NLT 5.0 
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Table No: 8.2 Specificity System Suitability Result  
S. 
No. 
Name of 
the 
solution 
Results obtained Acceptance criteria 
01 Blank 
No peak found in the 
retention time of principal 
peak 
No any peak should be found in the 
retention time of Artemether and 
Lumefantrine. 
02 Placebo 
No peak found in the 
retention time of 
principalpeak 
No any peak should be found in the 
retention time of Artemether and 
Lumefantrine. 
Discussion for Specificity 
 System suitability result passes with reference to the table no. 8.1- 8.2 and the 
results obtained for specificity are found within the acceptance criteria. The obtained 
results proved that there will not be blank and placebo interference in the Artemether 
and Lumefantrine peak by this assay method. The chromatograms were showed in 
chromatogram no.7.4 to 7.8. 
LINEARITY AND RANGE 
Table No: 8.3 Linearity Report 
S.No. Parameter 
Results obtained Acceptance 
criteria Artemether Lumefantrine 
01 
Tailing factor from five 
replicate injections 
1.03 2.28 NMT 3.0 
02 
Theoretical Plates from 
five replicate injections 
9061 4096 NLT 2000 
03 
% RSD of area for five 
standard injections 
0.030 0.027 NMT 2.0 % 
04 
Resolution between 
Artemether and 
Lumefantrine 
16.79 
 
NLT 5.0 
 
Chapter 8                                                                                     Result and Discussion 
 
Dept. of Pharmaceutial Analysis            141               J.K.K.Nattraja College of Pharmacy 
 
Table No. 8.4 Linearity Data Obtained From 60 % to 160 % of Artemether 
 
Figure 8.1 Linearity Graph Obtained for Artemether 
 
Table No. 8.5 Linearity Data Obtained From 60 % to 160 % of 
Lumefantrine 
y = 854.9x + 15980
R² = 0.999
0
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200000
300000
400000
500000
0.0 100.0 200.0 300.0 400.0 500.0 600.0
A
re
a 
(m
A
u
)
Concentration (mcg/mL)
LINEARITY OF ARTEMETHER STANDARD
Linearity level 
concentration 
in % 
Concentration of  
Artemether(mcg/mL) 
Standard 
area -1 
Standard 
area-2 
Average 
area 
60 192.0 179294 179233 179264 
80 256.0 237715 237510 237613 
100 320.0 290764 290592 290678 
120 384.0 339031 339391 339211 
160 512.0 455796 455684 455740 
Linearity 
level 
concentration 
in % 
Concentration 
of 
Lumefantrine 
(mcg/mL) 
Standard area 
-1 
Standard area-
2 
Average 
area 
60 72.0 2979334 2977800 2978567 
80 96.0 3983265 3979933 3981599 
100 120.0 4876621 4886428 4881525 
120 144.0 5662400 5663851 5663126 
160 192.0 7694804 7724812 7709808 
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Figure 8.2 Linearity Graph Obtained for Lumefantrine
 
Table No: 8.6 Linearity Results 
S.No. Parameter 
Results obtained Acceptance 
criteria Artemether Lumefantrine 
01 
Correlation 
coefficient 
0.99956 0.99911 NLT 0.998 
02 
Regression 
coefficient 
0.99911 0.9982 Informative 
03 
Residual sum of 
squares 
Not Applicable Informative 
04 Intercept 15980.01351 190449.3378 Informative 
05 
Slope of regression 
line 
854.9308488 38882.01492 Informative 
 
Discussion for Linearity 
System suitability result passes and the results obtained for linearity are found 
within the acceptance criteria with reference to the table 8.3 to 8.6. Hence it is 
concluded that the range of concentrations, 60 % to 160 % with respect to 100 % 
y = 4E+06x - 1E+07
R² = 0.9997
0
5000000
10000000
0.0 50.0 100.0 150.0 200.0 250.0A
re
a 
(m
A
u
)
Concentration (mg/mL)
LINEARITY OF LUMEFANTRINE STANDARD
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working concentration for assay method is linear for Artemether and Lumefantrine. 
The chromatograms were showed in chromatogram no.7.9 to 7.15. 
PRECISION  
System Precision 
Table No: 8.7 System Precision Reports for System Suitability 
S.No. Parameter 
Results obtained Acceptance 
criteria Artemether Lumefantrine 
01 
Tailing factor from five 
replicate injections 
1.03 2.32 NMT 3.0 
02 
Theoretical Plates from 
five replicate injections 
9096 4162 NLT 2000 
03 
% RSD of area for five 
standard injections 
0.100 0.089 NMT 2.0 % 
04 
% RSD of retention time 
for five standard injections 
1.03 2.32 NMT 1.0 % 
05 
Resolution between 
Artemether and 
Lumefantrine 
17 
 
NLT 5.0 
 
Table No: 8.8 System Precision Results for Artemether 
S. No. Retention Standard Area Tailing factor Theoretical plates 
01 4.36 289180 1.04 9380 
02 4.36 289578 1.05 9390 
03 4.36 288814 1.02 9391 
04 4.36 289411 1.02 9402 
05 4.36 289339 1.01 9418 
Mean 4.36 289264 1.03 9396 
Std dev 0.000 289.56 
NMT 3.0 NLT 2000 (RSD %) 0.00 0.100 
Limit NMT 1.0 % NMT 2.0 % 
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Table No: 8.9 System precision Result for Lumefantrine 
S. No. Retention Standard Area Tailing factor  Theoretical 
01 12.59 4972130 2.33 3836 
02 12.61 4911680 2.31 3854 
03 12.61 4913540 2.29 3848 
04 12.61 4927650 2.35 3841 
05 12.61 4932990 2.30 3834 
Mean 12.61 4931598.00 2.32 3843 
Stddev 0.009 24408.94 
NMT 3.0 NLT 2000 (RSD %) 0.07 0.49 
Limit NMT 1.0 % NMT 2.0 % 
 
Discussion for system precision: 
All the system suitability parameters were well within the desirable limits with 
reference to the table no.8.7 to 8.9, it indicates that the prescribed method is suitable 
to perform the estimation of Artemether and Lumefantrine from of Artemether and 
Lumefantrine for Oral Suspension (180 mg & 1080 mg).Further there was no 
deviation in the given method. The chromatograms were showed in the chromatogram 
no.7.16 to 7.17. 
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Method Precision (Repeatability) 
Table No: 8.10 System Suitability Result in Standard solution 
S.No. Parameter 
Results obtained Acceptance 
criteria Artemether Lumefantrine 
01 
Tailing factor from five 
replicate injections 
1.03 2.32 NMT 3.0 
02 
Theoretical Plates from five 
replicate injections 
9396 3843 NLT 2000 
03 
% RSD of area for five standard 
injections 
0.100 0.089 
NMT 2.0 
% 
04 
Resolution between Artemether 
and Lumefantrine 
17 
 
NLT 5.0 
 
Table No: 8.11 Method Precision Results for Artemether 
No. of 
Sample       
preparation 
Samples Area Results obtained 
Accepta
nce 
criteria 
Sample 
-1 
Sample 
-2 
Average 
Amount of 
drug 
present  
in mg 
 
Percenta
ge  of 
drug  
01 286806 287186 286996 180.43 100.24 
90
.0
%
 - 
11
0.
0%
 
02 285326 285340 285333 178.77 99.32 
03 286393 286196 286295 176.98 98.32 
04 285938 285770 285854 181.56 100.87 
05 287828 287882 287855 183.46 101.92 
06 289119 288834 288977 180.45 100.25 
 
Mean 100.15 
Std. Dev 1.242 
RSD 1.240 
NMT 
2.0 % 
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Table No.8.12 Method Precision results for Lumefantrine 
No. of 
Sample       
preparation 
Samples Area Results obtained 
Accept
ance 
criteri
a 
Sample -1 Sample -2 Average 
Amount 
of drug 
present  
in mg 
 
Percentage  
of drug  
01 4464462 4472208 4468335 1087.86 100.73 
90
.0
%
 - 
11
0.
0%
 
02 4456902 4462076 4459489 1073.71 99.42 
03 4429942 4429292 4429617 1066.51 98.75 
04 4456342 4458593 4457468 1079.18 99.92 
05 4489968 4495105 4492537 1081.66 100.15 
06 4441994 4443336 4442665 1075.60 99.59 
 
Mean 1077.42 
Std. dev 7.296 
RSD 0.677 
NMT 
2.0 % 
 
Discussion for Method precision: 
System suitability parameters were well within the prescribed limits with 
reference to the table no.8.10 to 8.12, which revealed that the prescribed procedure is 
capable to perform method precision using sample preparation. All the performed 
samples showed results between 90.0 % and 110.0 %.The method precision parameter 
complies as per In-House specification. The chromatograms were showed in 
chromatogram no.7.18 to 7.31. 
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ACCURACY 
Table No: 8.13 System Suitability Results for Accuracy 
S.No. Parameter 
Results obtained Acceptance 
criteria Artemether Lumefantrine 
01 
Tailing factor from five 
replicate injections 
1.03 2.28 NMT 3.0 
02 
Theoretical Plates from five 
replicate injections 
9061 4096 NLT 2000 
03 
% RSD of area for five 
standard injections 
0.030 0.027 NMT 2.0 % 
04 
Resolution between 
Artemether and 
Lumefantrine 
16.76 
 
NLT 5.0 
 
Table No: 8.14 Accuracy Results for Artemether 
Accuracy 
Level in 
% 
Artemether 
added in mg 
Artemether 
recovered in 
mg 
% 
Recovered 
Mean of 
% 
Recovered  
Acceptance 
criteria  
50 
0.159851 0.160055 100.13 
100.01% 
98
.0
 %
 - 
10
2.
0 
%
 
0.161044 0.160729 99.80 
0.160249 0.160407 100.10 
100 
0.318112 0.324047 101.87 
100.67% 0.322884 0.326964 101.26 
0.318112 0.314598 98.90 
150 
0.478759 0.481611 100.60 
100.55% 0.487109 0.495009 101.62 
0.481940 0.479169 99.43 
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Table No: 8.15 Accuracy Results for Artemether 
Accuracy 
Level in 
% 
Artemether 
added in mg 
Artemether 
recovered in 
mg 
% 
Recovered 
Mean of 
% 
Recovered  
Acceptance 
criteria  
50 
0.159851 0.160055 100.13 
100.01% 
98
.0
 %
 - 
10
2.
0 
%
 
0.161044 0.160729 99.80 
0.160249 0.160407 100.10 
100 
0.318112 0.324047 101.87 
100.67% 0.322884 0.326964 101.26 
0.318112 0.314598 98.90 
150 
0.478759 0.481611 100.60 
100.55% 0.487109 0.495009 101.62 
0.481940 0.479169 99.43 
 
Table No.8.16 Accuracy Results for Lumefantrine 
Accuracy 
Level in 
% 
Lumefantrine 
added in mg 
Lumefantrine 
recovered in 
mg 
% 
Recovered 
Mean of 
% 
Recovered  
Acceptance 
criteria  
50 
0.063263 0.064060 101.26 
100.66% 
98
.0
 %
 - 
10
2.
0 
%
 
0.064457 0.064684 100.35 
0.064059 0.064298 100.37 
100 
0.124139 0.125100 100.77 
100.66% 0.121353 0.122150 100.66 
0.122547 0.123206 100.54 
150 
0.187004 0.190144 101.68 
101.59% 0.183821 0.186764 101.60 
0.191778 0.194656 101.50 
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Discussion for Accuracy: 
System suitability result passes and the results obtained for accuracy are found 
within the acceptance criteria with reference to the table no.8.13 to 8.16. The 
chromatograms were showed in chromatogram no. 7.32 to 7.51. 
RUGGEDNESS (INTERMEDIATE PRECISION) 
Table No: 8.17 System Suitability Results for Ruggedness 
S.No. Parameter 
Results obtained Acceptance 
criteria Artemether Lumefantrine 
01 
Tailing factor from five 
replicate injections 
1.03 2.19 NMT 3.0 
02 
Theoretical Plates from five 
replicate injections 
9051 4158 NLT 2000 
03 
% RSD of area for five standard 
injections 
0.227 0.047 
NMT 2.0 
% 
04 
Resolution between Artemether 
and Lumefantrine 
17.1 
 
NLT 5.0 
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Table No: 8.18 Intermediate Precision Results for Artemether 
No. of 
Sample 
preparation 
Samples Area Results obtained 
Acceptan
ce 
criteria 
Sample -
1 
Sample 
-2 
Averag
e 
Amount 
of drug 
present 
in mg 
Percentage  
of drug 
1 273295 273115 273205 177.64 98.69 
90
.0
 to
 1
10
.0
 %
 
2 277150 277029 277090 178.34 99.08 
3 278416 278465 278441 176.83 98.24 
4 278493 278474 278484 179.85 99.92 
5 270769 270380 270575 178.97 99.43 
6 271712 271635 271674 176.64 98.13 
 
Average 98.91 
Std. Dev 0.695 
RSD 0.702 
NMT 2.0 
% 
Table No: 8.19 Intermediate Precision Results for Lumefantrine 
No. of 
Sample 
prepara
tion 
Samples Area Results obtained 
Accepta
nce 
criteria 
Sample -1 Sample -2 Average 
Amount 
of drug 
present 
in mg 
Percentage  
of drug 
1 4289102 4218029 4253566 1067.26 98.82 
90
.0
 %
 - 
11
0.
0 
%
 
2 4291352 4292318 4291835 1094.72 101.36 
3 4258195 4261537 4259866 1104.87 102.30 
4 4260643 4262731 4261687 1075.15 99.55 
5 4261898 4268101 4265000 1070.13 99.09 
6 4280265 4290892 4285579 1093.12 101.21 
 
Average 100.39 
Std. Dev 1.425 
RSD 1.420 NMT2% 
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Table No: 8.20 Combined Method Precision and Intermediate Precision Results 
for Artemether 
 
 
 
Sample preparation 
Results obtained 
Acceptance 
criteria 
Artemether drug 
release in mg 
Artemether drug 
release in % 
Method Precision-1 180.43 100.24 
90
.0
%
 - 
11
0.
0%
 
Method Precision-2 178.77 99.32 
Method Precision-3 176.98 98.32 
Method Precision-4 181.56 100.87 
Method Precision-5 183.46 101.92 
Method Precision-6 180.45 100.25 
Intermediate precision-
1 
177.64 98.69 
Intermediate precision-
2 
178.34 99.08 
Intermediate precision-
3 
176.83 98.24 
Intermediate precision-
4 
179.85 99.92 
Intermediate precision-
5 
178.97 99.43 
Intermediate precision-
6 
176.64 98.13 
Mean 99.53 
Std Dev 1.16 
% RSD 1.16 NMT 2.0 % 
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Table No. 8.21 Combined Method Precision and Intermediate Precision Results 
for Lumefantrine 
Sample preparation 
Results obtained 
Acceptance 
criteria 
Lumefantrine 
drug release in 
mg 
Lumefantrine drug 
release in % 
Method Precision-1 1087.86 100.73 
90
.0
%
 - 
11
0.
0%
 
Method Precision-2 1073.71 99.42 
Method Precision-3 1066.51 98.75 
Method Precision-4 1079.18 99.92 
Method Precision-5 1081.66 100.15 
Method Precision-6 1075.60 99.59 
Intermediate precision-
1 1067.26 98.82 
Intermediate precision-
2 1094.72 101.36 
Intermediate precision-
3 1104.87 102.30 
Intermediate precision-
4 1075.15 99.55 
Intermediate precision-
5 1070.13 99.09 
Intermediate precision-
6 1093.12 101.21 
Mean 100.08 
StdDev 1.11 
% RSD 1.11 NMT 2.0 % 
 
 
 
 
Chapter 8                                                                                     Result and Discussion 
 
Dept. of Pharmaceutial Analysis            153               J.K.K.Nattraja College of Pharmacy 
 
Discussion for Intermediate precision: 
System suitability result passes and the results obtained for Intermediate precision are 
found within the acceptance criteria with reference to the table no. 8.17 to 8.21. 
Combined Intermediate precision results and method precision results are also found 
well within the acceptance criteria. The chromatograms showed in the chromatogram 
no. 7.52 to 7.65. 
ROBUSTNESS 
Table No: 8.22 System suitability results for Artemether 
S. 
No. 
Parameter Name 
Artemether Results obtained 
Tailing factor Area (RSD) 
Theoretical 
Plates 
01 
Change in wavelength Plus 
212nm 
1.05 0.051 9382 
02 
Change in wavelength Minus 
208 nm 
1.04 0.051 9385 
03 Change in Flow rate 2.20 mL 1.03 0.087 9520 
04 Change in Flow rate 1.80 mL 1.05 0.178 8924 
05 Change in Mobile phase  plus 1.02 0.165 9068 
06 Change in Mobile phase minus 1.1 0.184 9057 
Acceptance criteria NMT 2.0  
NMT 
2.0% 
NLT 1000 
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Table No: 8.23 System suitability results for Lumefantrine 
S. 
No. 
Parameter Name 
Lumefantrine Results obtained 
Tailing 
factor  
Area 
(RSD) 
Theoretical 
Plates 
Resolution 
01 
Change in wavelength Plus 
212nm 
2.33 0.096 3838 16.58 
02 
Change in wavelength Minus 
208 nm 
2.23 0.102 3841 16.57 
03 
Change in Flow rate 2.20 
mL 
2.33 0.045 3610 16.52 
04 
Change in Flow rate 1.80 
mL 
2.31 0.124 4046 17.00 
05 
Change in Mobile phase  
plus 
2.20 0.146 4155 17.09 
06 
Change in Mobile phase 
minus 
2.20 0.070 4152 17.05 
Acceptance criteria 
NMT 
3.0 
NMT 
2.0% 
NLT 
1000 
NLT 5.0 
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Table No: 8.24 Robustness results obtained for Artemether 
 S. 
No. Parameter Name 
Results obtained 
Acceptance 
criteria Artemether 
drug in mg 
Artemether 
drug in % 
01 
Robust Wavelength 212 
nm 180.32 100.18 
 
90
.0
%
 - 
11
0.
0%
 
 
02 
Robust Wavelength 208 
nm 179.56 99.76 
03 Robust flow rate 2.2 mL 178.32 99.07 
04 Robust flow rate 1.8 mL 181.25 100.71 
05 
Robust mobile phase  
composition +5 % 178.69 99.27 
06 
Robust mobile phase  
composition  -5 % 179.92 99.96 
 
Table No: 8.25 Robustness results obtained for Lumefantrine 
 S. 
No. 
Parameter Name 
Results obtained 
Acceptance 
criteria 
Lumefantrine 
drug in mg 
Lumefantrine 
drug in % 
01 
Robust Wavelength 212 
nm 
1085.56 100.49 
 
90
.0
%
 - 
11
0.
0%
 
 
02 
Robust Wavelength 208 
nm 
1083.24 100.30 
03 Robust flow rate 2.2 mL 1084.54 100.42 
04 Robust flow rate 1.8 mL 1078.69 99.88 
05 
Robust mobile phase  
composition +5% 
1079.25 99.93 
06 
Robust mobile phase  
composition  -5% 
1086.23 100.58 
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Table No: 8.26 Combined Method precision and Robustness results obtained for 
Artemether 
S. No. Parameter Name 
Results obtained 
Artemether 
drug in mg 
Artemether 
drug  in % 
Acceptance 
criteria 
01 Method precision - 1 180.43 100.24 
90
.0
%
-1
10
.0
%
 
02 Method precision - 2 178.77 99.32 
03 Method precision - 3 176.98 98.32 
04 Method precision - 4 181.56 100.87 
05 Method precision - 5 183.46 101.92 
06 Method precision - 6 180.45 100.25 
07 
Robust Wavelength 212 
nm 
180.32 100.18 
08 
Robust Wavelength 208 
nm 
179.56 99.76 
09 Robust flow rate 2.2 mL 178.32 99.07 
10 Robust flow rate 1.8 mL 181.25 100.71 
11 
Robust mobile phase  
composition +5 % 
178.69 99.27 
12 
Robust mobile phase  
composition  -5% 
179.92 99.96 
Mean 99.99 
Std Dev 0.9458 
NMT 2.0% 
% RSD 0.9459 
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Table No: 8.27 Combined Method Precision and Robustness Results Obtained 
for Lumefantrine 
S. 
No. 
Parameter Name 
Results obtained 
Lumefantrine 
drug in mg 
Lumefantrine 
drug  in % 
Acceptance 
criteria 
01 Method precision – 1 1087.86 100.73 
90
.0
%
 - 
11
0.
0%
 
02 Method precision – 2 1073.71 99.42 
03 Method precision – 3 1066.51 98.75 
04 Method precision – 4 1079.18 99.92 
05 Method precision – 5 1081.66 100.15 
06 Method precision – 6 1075.60 99.59 
07 
Robust Wavelength 212 
nm 
1085.56 100.49 
08 
Robust Wavelength 208 
nm 
1083.24 100.30 
09 Robust flow rate 1.8 mL 1084.54 100.42 
10 Robust flow rate 2.2 mL 1078.69 99.88 
11 
Robust mobile phase  
composition +5 % 
1079.25 99.93 
12 
Robust mobile phase  
composition  -5 % 
1086.23 100.58 
Mean 100.01 
Std Dev 0.5632 NMT 2.0 
% % RSD 0.5631 
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Discussion for Robustness 
The results obtained for Robustness are found within the acceptance criteria 
with reference to the table no. 8.22 to 8.27. Combined method precision and 
robustness results are also found well within the acceptance criteria. The 
chromatograms showed in the chromatogram no. 7.66 to 7.89. 
STABILITY STUDIES 
Table No. 8.28   System suitability results and Cumulative % RSD results 
obtained for Stability of standard solution (Artemether) 
S. 
No. 
Time 
point 
Standard 
solution 
area  
Results obtained 
Cumulative 
% RSD 
Tailing 
factor 
obtained 
Theoretical plate 
obtained 
01 0 hour 289180 NA 1.01 9382 
02 3rd hour 289290 0.027 1.04 9387 
03 6th hour 289395 0.037 1.01 9401 
04 9th hour 289178 0.036 1.05 9378 
05 12th hour 288905 0.063 1.03 9409 
06 15th hour 289879 0.112 1.05 9415 
07 18th hour 288956 0.112 1.06 9317 
08 21st hour 288792 0.118 1.01 9358 
09 24th hour 289417 0.114 1.04 9417 
Limit NMT 2.0 % NMT 2.0 NLT 1000 
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Table No: 8.29 System suitability results and Cumulative % RSD results 
obtained for Stability of sample solution (Artemether) 
S. 
No. 
Time 
point 
Sample 
solution area  
Results obtained 
Cumulative 
% RSD 
Tailing factor obtained 
01 0 hour 286899 NA 1.01 
02 3rd hour 286597 0.074 1.06 
03 6th hour 286456 0.079 1.04 
04 9th hour 286954 0.083 1.05 
05 
12th 
hour 
286546 
0.078 1.06 
06 
15th 
hour 
286785 
0.071 1.01 
07 
18th 
hour 
286546 
0.068 1.03 
08 
21st 
hour 
286379 
0.073 1.06 
09 
24th 
hour 
286347 
0.077 1.03 
Limit NMT 2.0 % NMT 2.0 
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Table No: 8.30 System suitability results and Cumulative % RSD results 
obtained for Stability of standard solution (Lumefantrine) 
S. 
No. 
Time 
point 
Standard 
solution 
area  
Results obtained 
Cumul
ative 
% RSD 
Tailing 
factor 
obtained 
Theoretical 
plate 
obtained 
 
Resolutio
n 
01 0 hour 4972130 NA 2.19 4165 17.09 
02 3rd hour 4972651 0.007 2.18 4398 17.10 
03 6th hour 4973256 0.011 2.2 4157 17.09 
04 9th hour 4974785 0.023 2.17 4178 17.11 
05 
12th 
hour 
4972256 
0.022 2.2 4165 17.10 
06 
15th 
hour 
4973125 
0.019 2.19 4145 17.09 
07 
18th 
hour 
4977845 
0.041 2.20 4105 17.02 
08 21st hour 4964528 0.075 2.19 4018 17.09 
09 
24th 
hour 
4977136 
0.077 2.18 4187 17.09 
Limit 
NMT 
2.0 % 
NMT 3.0 NLT 1000 
NLT 3.0 
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Table No: 8.31 System suitability results and Cumulative % RSD results 
obtained for Stability of sample solution (Lumefantrine) 
S. No. 
Time 
point 
Sample 
solution 
area  
Results obtained 
Cumulative 
% RSD 
Tailing factor obtained 
01 0 hour       4871372 NA 1.96 
02 3rd hour 4892325 0.303 1.99 
03 6th hour 4852837 0.405 1.97 
04 9th hour 4902014 0.450 1.96 
05 12th hour 4910045 0.479 1.95 
06 15th hour 4899074 0.442 1.95 
07 18th hour 4874021 0.418 1.97 
08 21st hour 4872836 0.399 1.99 
09 24th hour 4882235 0.373 1.99 
Limit NMT 2.0 % NMT 3.0 
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Discussion for stability of analytical solutions: 
System suitability result passes with reference to the table no. 8.28 to 8.31 and the 
results obtained for stability of standard solution and sample solution are found within 
the acceptance criteria for the minimum period of 24 hours study. The chromatograms 
were showed in the chromatogram no.7.90 to 7.116. 
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9. CONCLUSION 
A RP-HPLC method for Artemether and Lumefantrine were developed and 
validated in powder for oral suspension dosage form as per ICH guidelines. The 
results are found to be complying with the acceptance criteria for each of the 
parameter. 
Acetonitrile and phosphate buffer of pH 2.3 in the ration of 45:55 v/v was 
used as mobile phase. The detection was carried out at 210 nm. The column was 
Zorbax SB C8 (250 x 4.6mm, 5µ). The flow rate was selected as 2mL/min 
Agilent HPLC (Open Lab software with DAD detector) with Zorbax SB C8 
(150X 4.6mm, 5µ) Packed Column, Injection volume of 20µL was injected and eluted 
with the Mobile phase (acetonitrile and phosphate buffer of pH 2.3 in the ration of 
45:55 v/v.) Which was pumped at a flow rate of 2.0 ml/min at 210nm.The peak of 
Artemether and Lumefantrine was found well separated at 4.3min, 12.3 min. The 
developed method was validated for various parameters as per ICH guidelines like 
system suitability, linearity, accuracy, precision, specificity, limit of detection, limit of 
quantitation, ruggedness, and robustness. The result obtained for the parameters were 
found well within the acceptance criteria. 
Hence it is concluded that the assay method is found to be valid in terms of 
precision, accuracy and specificity and hence it is suitable for routine analysis as well 
as for stability analysis. 
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